***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

COLLABORATION AND LICENSE AGREEMENT
 
This Collaboration and License Agreement (this “Agreement”) is made and entered
into effective as of July 11, 2011 (the “Effective Date”), by and between
Micromet AG, having its principal place of business at Staffelseestrasse 2,
81477 Munich, Germany (“Micromet”), Micromet, Inc., having its principal place
of business at 9201 Corporate Boulevard, Suite 400, Rockville, MD 20850 (solely
for the purpose of Section 16.4), and Amgen Inc., having its principal place of
business at One Amgen Center Drive, Thousand Oaks, CA 91320-1799, U.S.A.
(“Amgen”).  Micromet and Amgen each may be referred to herein individually as a
“Party,” or collectively as the “Parties.”
 
Recitals
 
A.           Micromet has developed a proprietary platform for the discovery,
research, and development of BiTE® antibodies, which may have applications in
the treatment of cancer.
 
B.           Amgen is a global biotechnology company with experience in the
development and commercialization of pharmaceutical products.
 
C.           Micromet and Amgen desire to collaborate on a research program with
respect to three potential drug targets and the development of BiTE antibody
products binding to one or two selected targets, and to have Amgen further
develop, manufacture and commercialize such products on a worldwide basis.
 
In consideration of the foregoing premises and the mutual promises and covenants
contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereby agree as
follows:
 
Agreement
 
1.
Definitions

 
When used in this Agreement, capitalized terms will have the meanings as defined
below and throughout this Agreement.
 
1.1         “Advance Payment” has the meaning set forth in Section 9.1.
 
1.2         “Affiliate” means, with respect to any Person, an entity that,
directly or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with such Person.  For purposes of
this definition only, “control” and, with correlative meanings, the terms
“controlled by” and “under common control with” means (a) the possession,
directly or indirectly, of the power to direct the management or policies of an
entity, whether through the ownership of voting securities, contract rights,
voting rights, corporate governance or otherwise, or (b) the ownership, directly
or indirectly, of more than 50% of the voting securities or other ownership
interest of an entity entitled to vote in the election of directors or similar
governing body, or if local law restricts foreign ownership, of the maximum
ownership percentage that may, under such local law, be owned by foreign
interests.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

 
1.3         “Alliance Manager” has the meaning set forth in Section 2.3.1.
 
1.4         “[***] Technology” means, with respect to a Product, any [***]
Technology that is developed [***] the [***] of the [***] for such Product and
is [***] for use by [***] for the Exploitation of [***] (other than those [***]
to a [***] (or, during the [***], to a [***])).
 
1.5         “[***] Technology” means any Patent or Know-How that is conceived or
generated solely by employees, agents or Service Providers of [***] or its
Affiliates pursuant to [***] this Agreement, but excluding any (a) [***]
Technology, (b) [***] Technology, (c) [***] Technology or (d) [***] or [***]
conceived or generated by [***] or its Affiliates pursuant to the [***] this
Agreement.
 
1.6         “Amgen Indemnitee” has the meaning set forth in Section 15.2.
 
1.7         “[***] Technology” means any Patent or Know-How that (a) is [***] or
its Affiliates during the Term and (b) is [***] of a Product, but excluding
[***] and any [***],[***],[***] or [***] or [***].
 
1.8         “Antibody” means a molecule comprising two or more immunoglobulin
variable domains or parts of such domains.
 
1.9         “Applicable Law” means the laws, rules, and regulations, including
any statutes, rules, regulations, guidelines, or other requirements (including
Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP) and Good
Clinical Practices (GCP), collectively referred to as “GxP”), that may be in
effect from time to time and apply to the Exploitation of a Product in the
countries of the Territory, including any such statutes, rules, regulations,
guidelines, or other requirements of the FDA or the EMA.
 
1.10       “Bankruptcy Code” has the meaning set forth in Section 14.5.2.
 
1.11       “Biosimilar Act” means the Biologics Price Competition and Innovation
Act of 2009 (or any amendment or successor statute thereto).
 
1.12       “BiTE Antibody” means any bi-specific, single-chain Antibody that
binds to the [***] of T cells and uses or is based upon Micromet’s proprietary
platform technology, including any such Antibody so generated pursuant to this
Agreement by or on behalf of Micromet, Amgen or any sublicensee under this
Agreement.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
2

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.13      “BLA” means a Biologics License Application, supplemental Biologics
License Application, or similar application filed or to be filed with the FDA,
as described in Title 21 of the U.S. Code of Federal Regulations, Part 601, et
seq., or a comparable application in jurisdictions outside the United States of
America, including a marketing approval application filed or to be filed with
the EMA.
 
1.14      “Breaching Party” has the meaning set forth in Section 13.3.1.
 
1.15      “Business Day” means any weekday that is not a legal holiday in New
York, New York, or Munich, Germany and is not a day on which banking
institutions in any of those cities are required by law or regulation to be
closed.
 
1.16      “Calendar Quarter” means any one of the four three-month time periods
in any calendar year commencing on January 1, April 1, July 1 and October 1 of
such year.
 
1.17      “Change of Control” means with respect to any entity (the “Acquired
Entity”) (a) any sale, exchange, transfer, or issuance to or acquisition by one
or more Third Parties of shares representing more than fifty percent (50%) of
the aggregate ordinary voting power entitled to vote for the election of
directors or similar governing body represented by the issued and outstanding
stock of the Acquired Entity or any Affiliate that directly or indirectly
controls the Acquired Entity (whether by sale or merger or otherwise, but
excluding the issuance of shares in bona fide financing transactions in which
multiple unaffiliated Third Parties participate where a majority of the members
of the board of directors or similar governing body of the Acquired Entity
remains unchanged), whether such sale, exchange, transfer, issuance or
acquisition is made directly or indirectly, beneficially or of record or in one
transaction or a series of related transactions; (b) a merger, reorganization or
consolidation under applicable law of the Acquired Entity with one or more Third
Parties as a result of which (i) the shareholders of the Acquired Entity or any
Affiliate that directly or indirectly controls the Acquired Entity immediately
prior to such merger, reorganization or consolidation do not continue to hold
immediately following the closing of such merger, reorganization or
consolidation at least fifty percent (50%) of the aggregate ordinary voting
power entitled to vote for the election of directors represented by the issued
and outstanding stock of the entity surviving or resulting from such
consolidation or (ii) the board of directors or similar governing body of the
Acquired Entity or any Affiliate that directly or indirectly controls the
Acquired Entity immediately prior to such merger, reorganization or
consolidation constitutes less than a majority of the members of the board of
directors or similar governing body of such Acquired Entity or any Affiliate
that directly or indirectly controls the Acquired Entity (or the surviving
entity) immediately following such merger, reorganization or consolidation; or
(c) a sale or other disposition of all or substantially all of the assets of the
Acquired Entity to one or more Third Parties in one transaction or a series of
related transactions; provided that, (x) in the case of subsections (a) and (b),
any transaction solely to change the domicile of the Acquired Entity shall not
be deemed a “Change of Control”, and (y) for all purposes of this Agreement,
when “Change of Control” is used with reference to Micromet, it shall be deemed
to include a reference to the ultimate parent of Micromet and any intervening
entities.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
3

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.18     “Co-Chair” has the meaning set forth in Section 2.1.1.
 
1.19     “Collaboration Target” means the target(s) selected from the
Feasibility Targets for further development after the end of the Feasibility
Phase, as further described in Section 3.5.
 
1.20     “[***] License” has the meaning set forth in Section 4.2.3(b).
 
1.21     “Commercialization” means the manufacture for commercial sale, and the
marketing, promotion, advertising, selling and distribution of a product after
Marketing Approval has been obtained.  The term “Commercialize” has a
correlative meaning.
 
1.22     “[***] Technology” means methods, technology, processes, analyses,
[***] plans and information relating to the [***] of the Products, including
[***] tools and analyses, [***] statements and strategies, [***] strategies and
analyses, [***] programs and materials, [***] materials and reports, [***]
planning and allocation, [***] data (whether [***] or otherwise), [***] data,
data [***], and analysis tools, and strategies and data relating to
[***],[***],[***] and the like.
 
1.23     “Commercially Reasonable Efforts” means the carrying out of obligations
or tasks by a Party using a level of efforts in good faith consistent with the
exercise of prudent scientific and business judgment, as applied by similarly
situated companies in the biopharmaceutical industry to products or research or
development candidates owned or licensed by it of similar scientific and
commercial potential.  Commercially Reasonable Efforts will take into account
the stage of development or commercialization, market potential and market size,
the product life cycle, the risk of development or Commercialization of the
product, the competitiveness of alternative products that are or are expected to
be in the marketplace (but excluding, in each case, any such products or
programs that are internal to the relevant Party or its Affiliates), the scope
and duration of patent rights or other proprietary rights related to the
product, the profitability of the product and alternative products and other
relevant commercial factors.  The term “Commercially Reasonable” has a
correlative meaning.
 
1.24     “Competing Product” has the meaning set forth in Section 8.8.1.
 
1.25     “Confidential Information” has the meaning set forth in Section 11.1.
 
1.26     “Control” means, with respect to a Party and any Patent, Know-How, or
other intellectual property right, that a Party owns or has a license to such
Patent, Know-How or intellectual property right and has the ability to grant to
the other Party a license or a sublicense (as applicable) to such Patent,
Know-How or intellectual property right on the terms and conditions set forth
herein without violating the terms of any agreement or other arrangement with
any Third Party existing at the time such Party would be required hereunder to
grant to the other Party such access, license or sublicense.  The term
“Controlled” has a correlative meaning.
 
1.27     “[***]” has the meaning set forth in Section 5.2.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
4

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.28     “Cost Overrun” has the meaning set forth in Section 9.2.2.
 
1.29     “[***] Technology” means, with respect to a Product, [***] and methods,
product [***] and [***] improvements for such Product, such as improvements that
increase [***],[***] or [***],[***] product [***] or decrease [***] or
[***].  Notwithstanding the foregoing, for purposes of [***] Technology, [***]
Technology, [***] Technology and [***] Technology, “[***] Technology” will
exclude any Patents or Know-How [***] for the [***] of a Product by means of
[***] (including [***] or [***]) (“[***] Technology”) except to the extent any
[***] Technology relates to the [***] of product [***], any form of [***], or
[***] improvements to the Product [***] or [***].
 
1.30     “Development Candidate” has the meaning set forth in Section 4.2.1.
 
1.31     “Development Plan” means the plan for the research and development of a
Product, as such plan may be amended in accordance with Section 4.1.2.
 
1.32     “Disclosing Party” has the meaning set forth in Section 11.1.
 
1.33     “Dispute” has the meaning set forth in Section 18.4.2.
 
1.34     “EMA” means the European Medicines Agency, or any successor agency
thereto.
 
1.35     “EU” means those countries, nations, states or other territories under
the jurisdiction of the EMA or any successor thereto, as such jurisdiction may
change from time to time.
 
1.36     “Exploit” means to research, develop, make, use, offer for sale, sell,
import, export, Commercialize or otherwise exploit a product, or have any of the
foregoing performed on a Party’s behalf.  The term “Exploitation” has a
correlative meaning.
 
1.37     “FDA” means the United States Food and Drug Administration, or any
successor agency thereto.
 
1.38     “Feasibility Phase” means the portion of the [***] that includes
certain [***] and [***] and other activities to be conducted by the Parties
commencing on the Effective Date, as further described in the Development Plan.
 
1.39     “Feasibility Report” has the meaning set forth in Section 3.4.
 
1.40     “Feasibility Targets” means the [***] or [***] and [***] of the targets
set out in Exhibit A, and any [***] of any such target.
 
1.41     “Field” means [***].

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
5

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.42     “First Commercial Sale” means, with respect to a Product in any
country, the first sale to a Third Party of a Product in such country after
Marketing Approval has been granted by the applicable Regulatory Authority in
such country.
 
1.43     “FTE” means the equivalent of a total of [***] hours per year of work
carried out by a qualified employee of a Party in accordance with the
Development Plan.  If any employee of a Party works partially on the execution
of the Development Plan and partially on other work, then the full-time
equivalent to be attributed to such individual’s work hereunder will be equal to
the percentage of such individual’s total work time that such individual spent
working on the execution of the Development Plan.  FTE work will not include the
work of [***] or [***], except to the extent included in the FTE Rate.
 
1.44     “FTE Rate” means €[***] per FTE, which amount is fully burdened and
includes without limitation, for each FTE, [***], and a pro rata [***] of [***]
and [***].
 
1.45     “Governmental Authority” means any supranational, national, federal,
state, local, municipal, quasi-governmental or other authority of any nature
(including any governmental division, subdivision, department, agency, bureau,
branch, office, commission, council, court or other tribunal) exercising
executive, legislative or judicial governmental powers.
 
1.46     “IND” means an Investigational New Drug Application filed or to be
filed with the FDA as described in Title 21 of the U.S. Code of Federal
Regulations, Part 312, and the equivalent application in jurisdictions outside
the United States of America, including an “Investigational Medicinal Product
Dossier” filed or to be filed with the EMA.
 
1.47     “Indemnification Claim Notice” has the meaning set forth in Section
15.3.
 
1.48     “Indemnified Party” has the meaning set forth in Section 15.3.
 
1.49     “Indemnifying Party” has the meaning set forth in Section 15.3.
 
1.50     “Indemnitee” has the meaning set forth in Section 15.3.
 
1.51     “Infringement” has the meaning set forth in Section 7.5.1.
 
1.52     “Initial Development Plan” has the meaning set forth in Section 4.1.1.
 
1.53     “[***] Technology” has the meaning set forth in Section 1.29.
 
1.54     “[***] Technology” means any Patent or Know-How conceived or generated
[***] by employees, agents, or Service Providers of [***] or [***] Affiliates
pursuant to [***] this Agreement.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
6

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.55     “[***]” means, with respect to a Product, the [***] and [***] of such
Product (including Research Candidates and Development Candidates related
thereto) commencing with the [***] and ending upon the later of (a) the receipt
by the [***] of the [***] from the [***] for such Product, or (b) the completion
of all [***] or [***] to be performed by [***] pursuant to the [***] for such
Product (including Research Candidates and Development Candidates related
thereto).
 
1.56     “JSC” has the meaning set forth in Section 2.1.1.
 
1.57     “Know-How” means (a) any scientific or technical information, results
and data of any type whatsoever, in any tangible or intangible form whatsoever,
that is not in the public domain or otherwise publicly known, including
databases, practices, methods, techniques, specifications, formulations,
formulae, protein sequences, DNA sequences, knowledge, know-how, skill,
experience, test data including pharmacological, medicinal chemistry,
biological, chemical, biochemical, toxicological and clinical test data,
analytical and quality control data, stability data, studies and procedures, and
manufacturing process and development information, results and data, and (b) any
biological, chemical, or physical materials that are not in the public domain or
otherwise available to the public; all to the extent not [***] or [***] in a
[***].
 
1.58     “Licensed Technology” means the [***] Technology, [***] Technology,
[***] Technology, [***] Technology, and [***] rights and interest in [***]
Technology, and any [***] Technology or [***] Technology to the extent included
in Licensed Technology pursuant to Sections 8.3 and 8.4, respectively.
 
1.59     “[***]” means [***], the successor-in-interest of [***] with respect to
the [***] Agreement, or any subsequent successor-in-interest thereto.
 
1.60     “[***] Agreement” means that certain [***] Agreement, dated [***], by
and between Micromet and [***], as amended.
 
1.61     “Losses” has the meaning set forth in Section 15.1.
 
1.62     “Major Market” means each of the United States, the United Kingdom,
Germany, France, Italy, Spain and Japan.
 
1.63     “[***] Technology” means, with respect to a Product, any improvements
to [***],[***] or [***] for such Product.
 
1.64     “Marketing Approval” means the approval of a BLA, and any [***] and
[***] to the extent required by Applicable Law prior to the sale of a
pharmaceutical product in a country.
 
1.65     “[***] Collaboration Expenses” means those costs and expenses incurred
by [***] after [***] directly in accordance with the [***], limited to the
following:

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
7

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

(a)           [***] associated with the [***] of any [***] performed by a [***]
for [***] in accordance with the [***] (and for clarity are not otherwise
included as part of the [***]);
 
(b)           [***]; and
 
(c)           any other costs or expenses [***] and included in the [***].
 
1.66     “[***] Technology” means any Patent or Know-How conceived or generated
solely by employees, agents or Service Providers of [***] or its Affiliates
pursuant to [***] this Agreement, but excluding any [***] Technology.
 
1.67     “[***] Collaborator” means any Third Party developing or
commercializing a product containing or comprising a [***] alone or in
collaboration with [***], in each case under a license to Patents Controlled by
[***].
 
1.68     “[***] Technology” means any Patent or Know-How that (a) is conceived
or generated by employees, agents or Service Providers of a [***] or its
Affiliates, either solely or jointly with employees, agents or Service Providers
of [***] or its Affiliates, in performing activities under a [***] or [***]
agreement with [***], (b) is Controlled by [***] during the Term, and (c) is
[***] for the [***] of a [***], but excluding any Patent or Know-How that, if it
had been generated by [***], would [***] Technology set forth in [***] of
Section [***] (unless separately licensed by [***] to [***]).
 
1.69     “[***] Technology” means any [***] Technology that is [***] for the
[***] of a [***].
 
1.70     “[***] FTE Costs” means, for all [***] performed by [***] in accordance
with the [***], the product of (a) the number of FTEs used by [***] for such
[***] as set forth in the [***] and (b) the [***]. For the avoidance of doubt,
the activity of contract personnel will be charged as Out-of-Pocket Costs.
 
1.71     “Micromet Indemnitee” has the meaning set forth in Section 15.1.
 
1.72     “[***] Technology” means any Patent or Know-How that (a) is [***]
Technology or [***] Technology, (b) becomes Controlled by [***] or its
Affiliates after the Effective Date, and (c) is [***] for the [***] of a [***],
but excluding (i) any [***] Technology, and (ii) any such Patent or Know-How
that is [***] for the [***] of such [***] on account of [***] or other [***]
made by [***] either to [***] or [***] following the [***] of the [***]
hereunder.
 
1.73     “[***] Technology” means any [***] Technology other than the [***]
Technology.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
8

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.74     “[***] Technology” means any Patent or Know-How that (a) is licensed
from a Third Party to [***] as of the Effective Date, and (b)(i) is [***] for
the [***] of a [***] (including the Patents licensed to [***] pursuant to the
[***] listed in [***]) or (ii) is [***] in its performance of [***] this
Agreement, but excluding any [***] Technology.
 
1.75     “[***] Technology” means any Patent or Know-How that (a) is owned by
[***] as of the Effective Date, and (b)(i) is [***] for the [***] of a [***]
(including the Patents listed in Exhibit C) or (ii) is [***] in its performance
of [***] this Agreement, but excluding any [***] Technology.
 
1.76     “[***]” means: (a) with respect to a Patent, that [***] the [***] of a
[***] or the [***] of a [***] would [***] the relevant Patent, and (b) with
respect to Know-How, that such Know-How is [***] and [***] the [***] or [***].
 
1.77     “Net Sales” means the gross amount invoiced or otherwise collected by
or on behalf of Amgen or its Affiliates or sublicensees for sales or other
commercial dispositions of Products to Third Party purchasers that are not
sublicensees of the selling party (which Third Party purchasers for purposes of
this definition will include bona fide Third Party distributors who purchase
Products from Amgen or its Affiliates at arm’s length transfer prices for resale
outside the United States, the EU and Japan so long as such distributor is not
granted a sublicense hereunder (other than an implied sublicense arising from
purchase of Products and rights to regulatory filings and related data)), less
the following deductions in each case to the extent allocated to such Product
and included in such invoice or otherwise actually allowed and taken with
respect to such sales, determined in accordance with IAS/IFRS (or GAAP for the
U.S.) consistently applied:
 
(a)           trade, cash, prompt payment and quantity discounts;
 
(b)           returns, allowances, rebates, chargebacks, and payments to
government agencies;
 
(c)           retroactive price reductions;
 
(d)           fees paid to distributors (that do not engage in marketing or
promotion of the Product and excluding any sales representatives of a Party or
any of its Affiliates and their respective sublicensees), group purchasing
organizations and managed care entities;
 
(e)           credits and allowances for product replacement, whether cash or
trade;
 
(f)           non-recoverable sales taxes, excise taxes, tariffs and duties
(excluding taxes when assessed on income derived from sales) imposed on Product
sales and separately included on the invoice;

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
9

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

(g)           bad debt to the extent actually tracked by the Amgen Finance
Department and, to the extent not so tracked, an allowance of [***] percent
([***]%), provided that, where actually tracked, any such amounts subsequently
recovered are treated as Net Sales;
 
(h)           freight or other transportation charges, insurance charges, and
additional special packaging and separately included on the invoice; and
 
(i)           as agreed by the Parties in writing (in each Party’s sole
discretion).
 
Net Sales in currency other than Euros will be translated into Euros according
to the provisions of Section 10.4 of this Agreement.  Sales between the Parties,
or between the Parties and their Affiliates or sublicensees, for resale to Third
Parties (who are not sublicensees of the selling party), will be disregarded for
purposes of calculating Net Sales; provided, that the subsequent sale to a Third
Party is included in Net Sales.  Any of the items set forth above that would
otherwise be deducted from the invoice price in the calculation of Net Sales but
which are separately charged to, and paid by, Third Parties will not be deducted
from the invoice price in the calculation of Net Sales.  In the case of any sale
of a Product for consideration other than cash, then for purposes of calculating
the Net Sales under this Agreement, such Product will be deemed to be sold
exclusively for money at the average sales price during the applicable reporting
period generally achieved for such Product in the country in which such sale or
other disposal occurred when such Product is sold alone and not with other
products.

Any disposal of Products for, or use of Products in, clinical or pre-clinical
trials, given as free samples, or distributed at no charge to patients unable to
purchase Product will not be included in Net Sales, in each case where no
amounts are received for such Product.

Where a Product is sold together with another therapeutically active ingredient
for a single price, including a Product sold together with another active
therapeutic ingredient as a combination product (a “Bundle”), then for the
purposes of calculating the Net Sales under this Agreement, such Product will be
deemed to be sold for an amount equal to (X/(X+Y)) * Z, where: X is the average
sales price during the applicable reporting period for such Product being sold
alone (in the same dosage form) in the particular country of sale; Y is the sum
of the average sales price during the applicable reporting period in the
particular country of sale, when sold alone, of each therapeutic (other than the
included Product(s)) included in the Bundle (in the same dosage form); and Z
equals the Net Sales of such Bundle.  In the event that a Product or one or more
of the other therapeutics in the Bundle are not sold separately (in the same
dosage form), the Parties will discuss in good faith and mutually agree (not to
be unreasonably withheld) on an equitable fair market price to apply to such
Product or other therapeutic in the Bundle.
 
A sale of a Product is deemed to occur upon the recognition of revenue in
accordance with U.S. GAAP.  Amgen, its Affiliates, and their respective
sublicensees will not (i) sell any Product in combination with or as part of a
bundle with other products of Amgen, its Affiliates or sublicensees, or (ii)
offer packaged arrangements to customers that include a Product, in either case
in such a manner as to disproportionately discount the selling price of such
Product as compared with the weighted-average discount applied to the other
products, as a percent of the respective list prices (or if not available, a
good faith estimate thereof) of such products and the Product prior to applying
the discount.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
10

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.78     “Non-Breaching Party” has the meaning set forth in Section 13.3.1.
 
1.79     “[***]” has the meaning set forth in Section 14.4.1.
 
1.80     “[***] Expenses” has the meaning set forth in Section 14.4.1.
 
1.81     “Out-of-Pocket Costs” means costs and expenses actually incurred and
paid to Third Parties by a Party and/or its Affiliates, if applicable.
 
1.82     “Patent” means (a) any patent or patent application in any country or
supranational jurisdiction, and (b) any provisional, substitution, division,
continuation, continuation in part, reissue, renewal, registration,
confirmation, reexamination, extension, supplementary protection certificate and
the like, of any such patent or patent application.
 
1.83     “Patent Challenge” has the meaning set forth in Section 8.9.1.
 
1.84     “Patent Challenger” has the meaning set forth in Section 8.9.1.
 
1.85     “Patent Coordinator” has the meaning set forth in Section 2.4.1.
 
1.86     “Patent Term Extension” has the meaning set forth in Section 7.7.
 
1.87     “Person” means any individual, corporation, partnership, firm,
association, joint venture, joint stock company, trust or other entity, or any
government or regulatory venture, joint stock company, trust or other entity, or
any government or regulatory administrative or political subdivision or agency,
department or instrumentality thereof.
 
1.88     “Phase 1 Trial” means a clinical trial of a pharmaceutical product
designed with the primary purpose of determining safety, metabolism and
pharmacokinetic properties and clinical pharmacology of such product and that
meets the definition of a Phase 1 study for the United States as described in 21
C.F.R. § 312.21(a), or its successor regulation, or the equivalent regulation in
any other  country, including the Phase 1 part of a Phase 1 / 2 Trial.
 
1.89     “Phase 1 / 2 Trial” means any clinical trial that is a combination
Phase 1 Trial and Phase 2 Trial.
 
1.90     “Phase 2 Trial” means a clinical trial of a pharmaceutical product,
following the completion of a Phase 1 Trial, designed to determine the safe and
effective dose range in the proposed therapeutic indication and that meets the
definition of a Phase 2 study for the United States as described in 21 C.F.R. §
312.21(b), or its successor regulation, or the equivalent regulation in any
other country.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
11

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.91     “Phase 2a Trial” means a limited, initial Phase 2 Trial typically
conducted in a smaller number of patients to demonstrate the effectiveness of a
Product for the proposed therapeutic indication.
 
1.92     “Phase 3 Trial” means a clinical trial of a pharmaceutical product on
patients designed to (a) establish that a drug is safe and efficacious for its
intended use; (b) define warnings, precautions and adverse reactions that are
associated with the drug in the dosage range to be prescribed; and (c) support a
Marketing Approval of such drug, and that meets the definition of a Phase 3
study for the United States as described in 21 C.F.R. § 312.21(c), or its
successor regulation, or the equivalent regulation  in any other country.
 
1.93     “Pivotal Trial” means (a) a Phase 2 Trial, or a combination Phase 2
Trial and Phase 3 Trial, that (taken together with any other trials completed
prior to or concurrently with such trial) is, if all endpoints are met,
sufficient to receive Marketing Approval for a pharmaceutical product by the
relevant Regulatory Authority in the indication under study, or (b) a Phase 3
Trial.
 
1.94     “[***] Patent” means all Patents in the [***] Technology, [***]
Technology, [***] Technology and [***] Technology, excluding all [***]
Patents.  By way of example, the Parties anticipate that Patents within the
[***] Technology and [***] Technology that relate primarily to any of the
following technologies that are not [***] to the [***] will be [***] Patents:
the [***] of a [***], the [***], the [***] used in [***], or the [***] of [***]
of an Antibody that is a [***].
 
1.95     “Product” means (a) any product comprising a BiTE Antibody binding to a
Collaboration Target, and (b) any derivative, modification or variant of the
foregoing that is, in each case, a [***].
 
1.96     “[***] Patent” means (a) all Patents in the [***] Technology and the
[***] Technology and (b) all Patents in the [***] Technology and the [***]
Technology that relate primarily to the [***] or the [***] of a [***] (or,
during the [***], of a [***] directed to a [***]).
 
1.97     “Program Transfer” has the meaning set forth in Section 14.1.
 
1.98     “[***]” means, with respect to a product and certain Patents or
Know-How, that the [***] of such [***] by a Party would be: (a) [***], or [***],
or (b) [***] to [***], in each case without the [***] of an [***] in such [***]
or the [***] of such [***] (or a reasonable substitute therefor that is not
Controlled by such Party).
 
1.99     “Receiving Party” has the meaning set forth in Section 11.1.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
12

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.100   “Recovery” has the meaning set forth in Section 7.5.2(c).
 
1.101   “Regulatory Authority” means, in a particular country or jurisdiction,
any Governmental Authority involved in granting approval to market or sell a
Product, including any pricing and reimbursement approvals, in such country or
jurisdiction, including the FDA, the EMA, and any Governmental Authority
equivalent to and performing some or all of the functions of the FDA or EMA in
the applicable jurisdiction.
 
1.102   “Regulatory Filing” means any submission or application made or filed
with a Regulatory Authority, including any IND or BLA.
 
1.103   “Research Candidate” means any BiTE Antibody (or component thereof)
binding to a Feasibility Target and generated under the Development Plan.
 
1.104   “Reverted Product” has the meaning set forth in Section 14.1(h).
 
1.105   “Royalty Term” has the meaning set forth in Section 9.4.2.
 
1.106   “[***]” has the meaning set forth in Section 8.8.3.
 
1.107   “SEC” means the U.S. Securities and Exchange Commission or any non-U.S.
equivalent thereto.
 
1.108   “Selection Period” means, with respect to a [***], the period commencing
on the Effective Date and ending upon the later of (a) [***] ([***])[***] after
submission of the final [***] for such [***] to the [***] pursuant to Section
3.4 and (b) [***].
 
1.109   “Senior Officer” has the meaning set forth in Section 2.1.5(b).
 
1.110   “Service Provider” has the meaning set forth in Section 4.5.
 
1.111   “Taxes” has the meaning set forth in Section 10.2.1.
 
1.112   “[***]” means a [***] (comprising one or more [***]) that as its primary
[***] of [***] both a [***] and a [***] and thereby [***] the [***] to [***] of
the [***], but excluding any [***].
 
1.113   “Term” has the meaning set forth in Section 13.1.
 
1.114   “Terminated Product” has the meaning set forth in Section 14.2.1.
 
1.115   “[***]” has the meaning set forth in Section 14.2.1.
 
1.116   “[***]” has the meaning set forth in Section 14.2.2.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
13

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

1.117   “[***]” has the meaning set forth in Section 14.2.2.
 
1.118   “[***]” has the meaning set forth in Section 14.2.2.
 
1.119   “Termination Effective Date” has the meaning set forth in Section
14.1(a).
 
1.120   “Territory” means all countries of the world.
 
1.121   “Third Party” means any entity other than Micromet, Amgen or their
respective Affiliates.
 
1.122   “Third Party Claim” has the meaning set forth in Section 15.1.
 
1.123   “Transferred Trial” has the meaning set forth in Section 14.1(b).
 
1.124   “United States” or “U.S.” means the United States of America (including
the District of Columbia).
 
1.125   “[***] Technology” has the meaning set forth in Section 8.6.5(a).
 
1.126   “[***]” means any of the agreements listed in [***].
 
1.127   “[***]” means a product that itself is or contains an [***] to [***]
directed against the [***] in order to [***] or [***].
 
1.128   “Valid Claim” means (a) an [***] of an [***] that has not (i) expired or
been canceled, (ii) been declared invalid by a decision of a court or other
appropriate body of competent jurisdiction, from which no appeal is or can be
taken, (iii) been admitted to be invalid or unenforceable through reissue,
disclaimer or otherwise, or (iv) been abandoned or disclaimed, and (b) a claim
included in a pending patent application that is being actively prosecuted and
that has not been (i) canceled, (ii) withdrawn from consideration, (iii) finally
determined to be unallowable by the applicable governmental authority (from
which no appeal is or can be taken), or (iv) abandoned or disclaimed; provided,
however, that if more than [***] ([***])[***] have elapsed from the date to
which such claim takes priority, such claim will not constitute a Valid Claim
for the purposes of this Agreement unless and until a Patent issues with such
claim and meets the requirements of clause (a) above.  For purposes of this
Agreement, a claim of a Patent or patent application that has [***], pursuant to
Section 18.4.3(b), [***] to be [***], will [***] a Valid Claim.
 
1.129   “VAT” has the meaning set forth in Section 10.2.1.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
14

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

2.           Collaboration Governance
 
2.1          Joint Steering Committee.
 
2.1.1       Establishment of Joint Steering Committee.  The Parties will
establish a joint steering committee (the “JSC”) within thirty (30) days of the
Effective Date, to oversee the performance of the Development Plan.  Each Party
will appoint three (3) employees with senior level authority and expertise to
serve as their representatives on the JSC.  From time to time, on written notice
to the other Party, Micromet and Amgen each may substitute any of its
representatives on the JSC.  Each Party will designate one of its members of the
JSC as the “Co-Chair.”  Subject to the provisions of this Section 2, the JSC
will establish its own procedural rules for its operation.
 
2.1.2       Tasks of the JSC.  The JSC will have the power only to: (a) oversee
the [***] for each Product and the collaboration of the Parties under this
Agreement; (b) following completion of the [***], discuss the continued
development of the Products; (c) monitor the activities and performance of the
JPT; (d) review and approve in writing any updates or amendments to the
Development Plan, including the [***] Collaboration Expenses; and (e) take such
other actions as are expressly delegated to the JSC in this Agreement.  The JSC
will not have any power to amend this Agreement or to waive compliance with the
terms hereof.
 
2.1.3       JSC Meetings.  Initially, the JSC will meet once every Calendar
Quarter. Following the completion of the [***], the JSC will meet
semi-annually.  Following the First Commercial Sale of a Product in a Major
Market, the JSC will meet annually.  Meetings may be held in person or by means
of telecommunication (telephone, video, or web conferences); provided, however,
that at least one meeting per year will be held in person.  The JSC may meet
more frequently by agreement of the Co-Chairs.  The Co-Chair of a Party,
alternating with the Co-Chair of the other Party, will be responsible for
organizing the meetings of the JSC and for distributing the agenda of the
meetings.  The organizing Co-Chair will include on the agenda any item within
the scope of the responsibility of the JSC that is requested to be included by
any member of the JSC, and will distribute the agenda to the JSC no less than
one week before the meeting.  Each Party may, in its discretion, invite
non-voting employees, consultants or advisors (which consultants and advisors
will be under an obligation of confidentiality no less stringent than the terms
set forth in Article 11) to attend any meeting of the JSC.
 
2.1.4       Meeting Minutes.  The Co-Chair who organized the JSC meeting (or his
or her designee) will prepare the meeting minutes within seven (7) Business Days
after each meeting, and will send it to all members of the JSC for review and
approval.  Minutes will be deemed approved unless any member of the JSC objects
to the accuracy of such minutes by providing written notice to the other members
of the JSC within fourteen (14) Business Days of receipt of the minutes.  In the
event of any such objection that is not resolved by mutual agreement of the
Co-Chairs, such minutes will be amended to reflect such unresolved objection.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
15

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

2.1.5       Decision Making.
 
(a)           The JSC will take action on matters within its power by unanimous
consent of the members of the JSC, with each Party having a single vote,
irrespective of the number of JSC members in attendance at a meeting, or by a
written resolution signed by the Co-Chairs.
 
(b)           If the JSC is unable to reach unanimous consent on a matter that
[***] to the [***] contemplated by this Agreement, then the matter may be
escalated, by written notice of either Party, to the “Senior Officer” of each
Party (who will initially be (i) in the case of Micromet, [***], and (ii) in the
case of Amgen, [***]).  The Senior Officers (or their respective designees, who
must each be a senior executive with a title of “Senior Vice President” or
higher with appropriate decision-making authority, but may not be members of the
JSC or JPT, or the Alliance Manager) will meet at least once in person to
discuss such matter and use their good faith efforts to resolve the unresolved
matter within thirty (30) days after the matter has been escalated to the Senior
Officers.  If the Senior Officers (or their designees) cannot reach agreement on
how to resolve such matter within such period, then the [***] will have the
authority to [***] on the matter in lieu of the [***] of the [***].  With
respect to all other matters on which the [***] is [***],[***] (after [***] in
[***] the [***] of [***]) will have the authority to [***] a [***] on the matter
in lieu of the [***] of the [***] of the [***].
 
(c)           Notwithstanding the terms of Section 2.1.5(b), [***] Senior
Officer will not have the authority to [***] a [***] that would (i) materially
alter the [***] activities described in the [***], or [***] the [***] reflected
in such [***], (ii) [***] the [***] of [***] of [***], or [***] or [***]
obligations or [***] expenses, under the [***], or (iii) have a [***] on [***]
for the [***] and [***] of [***].  Any decision described in this Section
2.1.5(c) will be mutually agreed by the Parties, with disputes resolved pursuant
to the resolution mechanism described in Section 18.4.
 
(d)           Notwithstanding the terms of Sections 2.1.5(b) and (c) above, if
the matter concerns a dispute regarding the interpretation of this Agreement,
the performance or alleged nonperformance of a Party’s obligations under this
Agreement, or any other alleged breach of this Agreement, such matter will be
resolved in accordance with the terms of Section 18.4.
 
2.1.6       [***] of JSC Upon [***].  If [***] is the subject of a [***] by a
[***] (defined below), then [***] (or its successor) will provide [***] with
written notice within five (5) Business Days following the [***] of such
[***].  [***] may elect to [***] the JSC by delivering written notice to [***]
within [***] ([***]) days after the later of [***] of such [***] or receipt of
such notice.  Following any such [***],[***] will (a) have the right to [***],
solely and exclusively [***], all [***] pursuant to this Agreement to the [***]
and (b) provide [***] with [***] with respect to Products that are under
development in [***], and a summary annual [***] with respect to [***].  For
purposes of this Section 2.1.6, a “[***]” means a Third Party that has a [***]
of at least [***] or has [***] of at least [***] from the [***] of [***].

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
16

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

2.2          Joint Project Team.
 
2.2.1       Establishment of Joint Project Team.  The Parties will establish a
joint project team (the “JPT”) to oversee the performance of the research and
development of Products under the [***].  The JPT will consist of an equal
number of representatives of each Party designated by the JSC.  Each Party will
designate one of its JPT members as the project team leader (each a “JPT
Leader”) who will be the primary contact person for the other Party for all
operational matters relating to the development of a Product by such
Party.  From time to time, on written notice to the other Party, Micromet and
Amgen each may substitute any of its representatives on the JPT.  Upon
completion of the [***], the JPT will [***].
 
2.2.2       Tasks of the JPT.  The JPT will: (a) oversee the day-to-day
activities of the Parties in the performance of the Development Plan; (b)
develop and propose updates to the Development Plan for review and approval by
the JSC in accordance with Section 2.1.2, including any [***] or [***],[***],
the [***] and [***] for [***] and [***] approved by the JSC; (c) provide a
quarterly written report to the JSC summarizing the Parties’ progress with
respect to the [***] of the Feasibility Targets or the [***] of Products, as
applicable; and (d) take such other actions as are expressly delegated to the
JPT by the JSC or by the terms of this Agreement. The JPT will not have any
power to amend this Agreement or to make decisions assigned to the JSC, and will
have only such powers as are specifically delegated to it by the JSC or the
terms of this Agreement.
 
2.2.3       JPT Meetings.  The JPT will meet in full or in subgroups as often as
required for the performance of the Development Plan, but not less than once
every Calendar Quarter prior to the JSC meeting. Meetings may be held in person
or by means of telecommunication (telephone, video, or web conferences);
provided, however, that at least two meetings per year will be held in
person.  The JPT Leaders will be responsible for establishing the meeting
schedule, and will alternate in organizing the meetings of the JPT.  The JPT
Leader organizing a JPT meeting will be responsible for distributing the agenda
of the meeting.  The organizing JPT Leader will include on the agenda any item
within the scope of the responsibility of the JPT that is requested to be
included by any member of the JPT, and will distribute the agenda to the JPT no
less than one week before the meeting.  Each Party may, in its discretion,
invite non-voting employees, consultants or advisors (which consultants and
advisors will be under an obligation of confidentiality no less stringent than
the terms set forth in Article 11) to attend any meeting of the JPT.
 
2.2.4       Meeting Minutes.  The JPT Leader who organized the JPT meeting (or
his or her designee) will prepare the meeting minutes within seven (7) Business
Days after each meeting, and will send it to all members of the JPT for review
and approval.  Minutes will be deemed approved unless any member of the JPT
objects to the accuracy of such minutes by providing written notice to the other
members of the JPT within fourteen (14) Business Days of receipt of the
minutes.  If any such objection is not resolved by mutual agreement of the JPT
Leaders, such minutes will be amended to reflect such unresolved objection.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
17

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

2.2.5       Decision Making.  The JPT will agree on proposals and
recommendations to the JSC on all matters within the responsibility of the JPT
by unanimous consent, with each Party having a single vote, irrespective of the
number of JPT members in attendance at a meeting, or by a written resolution
signed by the JPT Leaders.  All proposals and recommendations of the JPT will be
submitted for approval by the JSC at the subsequent JSC meeting.  If the JPT is
unable to reach unanimous consent on a particular matter, such matter will be
submitted to the JSC for resolution in accordance with Section 2.1.5.
 
2.3          Alliance Managers.
 
2.3.1       Appointment.  Each of the Parties will appoint a single individual
to act as a single point of contact between the Parties to facilitate the
effective exchange of information between the Parties and discuss the
performance of this Agreement (each an “Alliance Manager”). Each Party may
change its designated Alliance Manager from time to time upon written notice to
the other Party. Any Alliance Manager may designate a substitute to temporarily
perform the functions of that Alliance Manager by written notice to the other
Party.
 
2.3.2       Responsibilities. The Alliance Managers will use reasonable efforts
to attend all JSC and JPT meetings and support the Co-Chairs in the discharge of
their responsibilities. Alliance Managers will be nonvoting participants in the
JSC and JPT meetings, unless they are also appointed members of the JSC.  Each
Alliance Manager will be charged with fostering a collaborative work environment
within and among the JSC and JPT. In addition, each Alliance Manager (or his or
her designee) will: (a) coordinate the interactions between the relevant
functional representatives of the Parties, (b) identify and bring disputes to
the attention of the JSC in a timely manner, (c) assist with governance
activities, such as the conduct of required committee meetings and drafting of
meeting minutes, and (d) ensure that relevant action items resulting from such
meetings are appropriately carried out or otherwise addressed.  From time to
time following the completion of the [***], each Party may reasonably request
that the Alliance Managers facilitate a meeting between appropriate executives
or other personnel of the Parties to discuss any issues relevant to the
relationship of the Parties under this Agreement and the current status of the
Product.
 
2.4          Patent Coordinators.
 
2.4.1       Appointment.  Each of the Parties will appoint a single individual
to act as a primary point of contact between the Parties to facilitate the
effective exchange of information between the Parties relating to the
prosecution, maintenance and enforcement of [***] Patents, [***] Patents and
[***] Technology (each a “Patent Coordinator”).   Each Party may change its
designated Patent Coordinator from time to time upon written notice to the other
Party. Any Patent Coordinator may designate a substitute to temporarily perform
the functions of that Patent Coordinator by written notice to the other Party.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
18

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

2.4.2       Patent Coordinator Meetings and Responsibilities. The Patent
Coordinators will meet as often as reasonably requested by either Patent
Coordinator, but not less than once per calendar year.  Meetings may be held in
person or by means of telecommunication (telephone, video, or web conferences)
as the Patent Coordinators agree.  The Patent Coordinators will discuss and
oversee Patent-related activities hereunder.
 
3.           Feasibility Phase
 
3.1      Activities During Feasibility Phase.  The Feasibility Phase is designed
to [***] that [***] to the [***] and support the selection of one or more
Feasibility Targets as Collaboration Targets for further BiTE development.  The
Feasibility Phase is scheduled for completion over the [***] commencing on the
Effective Date, but will be [***] to [***] the [***].  The [***] includes a
budget of [***] to be incurred during the Feasibility Phase.  During the
Feasibility Phase, the JPT will periodically review and propose amendments to
the Development Plan for approval by the JSC, to reflect the progress achieved
and the further [***] to be undertaken by the Parties in the [***] of the [***]
and the generation of [***].
 
3.2      Feasibility [***].  During the [***] commencing on the Effective Date,
if one of the [***] the [***] described in the Development Plan, or if [***]
otherwise [***] that it is [***] to continue the [***] of a [***] and the [***]
of a [***] against such [***] would [***] in a [***] with [***], a [***], or
other [***] that [***] proceeding with [***], then upon written notice to
[***],[***] may [***] such [***] with another [***] in accordance with the terms
of this Section 3.2.  Such notice will include (i) [***] and a [***] rationale
for [***] the [***], and (ii) a full description of each [***], in substantially
the same format as the [***], and a [***] rationale for each [***].  Within ten
(10) Business Days after receipt of such written request, [***] will notify
[***] which [***], if any, are [***] to [***], in its [***].  If [***] is [***]
to [***], then the Parties will schedule a scientific meeting (or
teleconference) to discuss such [***] and the [***] thereof promptly after [***]
receipt of such notice.  Promptly following such scientific meeting, [***] will
notify [***] in writing which [***] has been [***] as a [***], at which time
such [***] will be [***] a [***] hereunder and the Parties, through the JPT with
approval from the JSC, will update the [***] within the [***] accordingly.  If
[***] notifies [***] that [***] of the [***] are [***], then [***] will have the
opportunity to [***] additional [***] through the [***] process set forth above
until a [***] is identified and agreed by the Parties (or [***] determines not
to further [***]).  If a [***] has not been identified and agreed by the Parties
within [***] ([***])[***] after [***] receipt of the initial request identifying
[***], then either Party may escalate such matter to the Senior Officers of the
Parties, who will discuss such matter and use their good faith efforts to
resolve the unresolved matter within thirty (30) days after the matter has been
escalated.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
19

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

3.3      Diligence.  Micromet will diligently perform the activities assigned to
it in the Development Plan for the Feasibility Phase (including generating [***]
to the [***]).  Amgen will diligently perform the activities assigned to it in
the Development Plan for the Feasibility Phase.  All efforts of a Party’s
Affiliates, sublicensees and Service Providers will be considered efforts of
such Party for the purpose of determining such Party’s compliance with its
obligations under this Section 3.3.
 
3.4      Reports; Final Report.  During the Feasibility Phase, each Party will
provide through the JPT regular reports to the JSC detailing its activities
under the Development Plan and the results of such activities.  Within [***]
([***]) days after the Effective Date, the Parties will agree upon the elements
of the final report to be generated pursuant to the Feasibility Phase (such
report, the “Feasibility Report”).  Upon completion of the Feasibility Phase,
the JPT will generate and approve the final Feasibility Report and submit it to
the JSC for approval.
 
3.5      Selection of Collaboration Target.  Following completion of the
Feasibility Phase and the submission of the final Feasibility Report to the JSC
pursuant to Section 3.4, or at such earlier time as Amgen elects, Amgen will
notify Micromet in writing of its determination prior to the expiration of the
Selection Period whether zero, one or two Feasibility Targets (and which
Feasibility Targets, if any) will be selected as Collaboration Targets for
further development under the Development Plan (which Feasibility Targets are
not required to be selected simultaneously).  With respect to any Feasibility
Targets [***] (or [***] under Section 3.2) as of the [***] of the [***] (or
earlier, to the extent [***] notifies [***] in writing [***] such Feasibility
Target), (i) [***] will be [***] this Agreement at will for all [***] to [***]
(and not [***] to a [***] for which this Agreement has [***]) pursuant to
Section [***] and (ii) the [***] of Sections [***] and [***] will apply with
respect to such [***] as to any [***] Technology and [***] Technology,
respectively, applicable to such [***], solely for use in [***] and [***]
directed to such [***] (and not [***] to a [***] for which this Agreement has
[***]).  Notwithstanding anything to the contrary in this Agreement, if [***]
does not select [***] prior to the [***] of the [***], then [***] will be [***]
to have [***] this Agreement [***] pursuant to Section [***] effective upon
[***] of the [***].
 
4.           Development Program.
 
4.1          Development Plan and Amendments.
 
4.1.1       Development Plan.  An initial Development Plan for the initial
Product, covering the Feasibility Phase through the first IND filing, is
attached as Exhibit B (the “Initial Development Plan”).  Within [***]
([***])[***] following the selection of any Collaboration Target pursuant to
Section 3.5, the Parties through the JPT with approval from the JSC will update
the Initial Development Plan to account for the selected Collaboration
Target.  In the event that two Collaboration Targets are selected pursuant to
Section 3.5, Amgen will determine which Collaboration Target program will be
initiated first.  The Development Plan will include a budget of [***]
Collaboration Expenses to be incurred pursuant to the Development Plan.  The
Development Plan will set appropriate objectives and timelines for carrying out
development activities sufficient in scope and quality to progress the
development of a Product towards Marketing Approval using Commercially
Reasonable Efforts.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
20

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

4.1.2       Development Plan Amendments.  During the [***], the JPT will
periodically review and propose amendments to the Development Plan for approval
by the JSC, to reflect the progress achieved and the further development
activities to be undertaken by the Parties in the development of a Product, but
not less than once every year in conjunction with the Parties’ budget and
program review cycle.  After completion of the [***], the Development Plan will
be updated by Amgen in a manner consistent with the annual development plans for
Amgen’s other clinical product programs and the terms of this Agreement, and a
summary of any such updates will be provided to Micromet together with the
progress reports delivered pursuant to Section 4.4.
 
4.1.3       Multiple Collaboration Targets.  If Amgen has selected two
Collaboration Targets, then the JSC will create an additional Development Plan
for the second such Product within [***] ([***])[***] after the [***] of the
[***].  Such Development Plan will be based on the Initial Development Plan
attached to this Agreement (but excluding the activities relating to the
Feasibility Phase) and adjusted based on the selected Collaboration
Target.  [***] will reasonably determine the timeline for initiation of the
second Collaboration Target program under such plan; provided, that such program
will commence [***] after the start of the first Collaboration Target program
but in no event later than [***] ([***])[***] after the start of the first
Collaboration Target program, unless otherwise agreed by the Parties.
 
4.2          Allocation of Responsibilities.  Each Development Plan for a
Product will reflect the following allocation of responsibilities:
 
4.2.1       BiTE Antibody Generation and Research.  Micromet will be responsible
for conducting the generation, engineering and optimization of BiTE Antibodies
(including the Research Candidates) binding to a Collaboration Target in
accordance with the Development Plan.  Amgen will provide certain [***] for
[***] in the [***] of BiTE Antibodies, as specified in the Development
Plan.  The JPT will propose BiTE Antibody candidates for Amgen to
review.  Amgen, in consultation with the JSC, may select one or more BiTE
Antibodies binding to the Collaboration Target for further development as a
Product (each a “Development Candidate”).
 
4.2.2       Preclinical Development.  Micromet will be primarily responsible for
(i) conducting [***] of BiTE Antibodies binding to the Collaboration Target,
(ii) the development of [***] and conducting of [***] during [***] in [***] and
(iii) performing [***] and [***] of the Products.  Micromet will (a) perform
such activities in accordance with the Development Plan, (b) keep Amgen apprised
of all such activities and the results thereof, (c) provide Amgen with a
reasonable opportunity to provide comments on the performance of any such
activities, and (d) reasonably incorporate such feedback in its performance of
such activities.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
21

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

4.2.3      [***] and [***].
 
(a)           Micromet will perform [***]—consisting of [***] of [***] and [***]
for [***] and [***]—and [***] quantities of [***] for [***].  The foregoing
activities will be conducted in accordance with the Development Plan, and the
costs of such work will be in the [***] Collaboration Expenses.
 
(b)           Upon completion of its development of the [***], Micromet will
[***] to Amgen the [***], the [***], proposed [***], and other information,
documentation and materials (including [***]) as reasonably required by Amgen to
[***] the [***] in its [***].  If the Development Plan calls for the
incorporation of [***] or [***] into the [***] for the Products, then
(i) Micromet will keep Amgen informed regarding the status of [***] with [***],
(ii) Micromet’s [***] of [***] and [***], and Amgen’s rights to use such
[***] and [***], will be subject to the terms of [***], (iii) at Amgen’s request
following [***] to [***] one or more [***] under Sections 3.7 and 4.8 of the
[***] with respect to the Products, Micromet will [***] and use commercially
reasonable efforts to [***] (taking into account Amgen’s input) (such agreement
entered into between Micromet and [***], a “[***]”), which [***] will be subject
to the [***] of [***] described in Section [***] with respect thereto and [***]
to Amgen hereunder, and which [***] technology will be deemed [***] Technology,
(iv) prior to the [***] of any [***] (or [***] between Amgen and [***] with
respect to the Products in lieu of a [***]), Micromet will not take or fail to
take any action that will [***] under Section 3.7 or 4.8 of [***], and
(v) unless Amgen requests otherwise, Micromet will [***] and refrain from [***]
(as such terms are defined in the [***]) in connection with the activities
contemplated by this Agreement.
 
(c)           Amgen or its designee will be responsible for [***] to [***] and
[***], further [***] and the [***] of any BiTE Antibody used in the Product and
all [***] and [***] of the [***] for [***] and for [***], and for any other
[***].  In addition, Micromet and Amgen will [***] certain [***] as further
detailed in the Development Plan.
 
(d)           If a Party will manufacture and supply Product to the other Party
for the performance of clinical trials, the Parties will enter into a quality
agreement describing the responsibilities of each Party relating to quality
control and release of the Product and a pharmacovigilance agreement relating to
the handling and exchange of any safety information and adverse event reports.
 
4.2.4      Clinical Development.  The Parties will collaborate on the clinical
development of Products as described in this Section 4.2.4.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
22

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

(a)           Phase [***] Trials.  Amgen will draft the clinical protocols for
[***] Trials and [***] Trials for the Products for review and endorsement by the
JPT and the JSC.  Amgen will be responsible for the performance of all clinical
trials of Products and associated regulatory activities.  During the [***],
(i) Micromet will participate in the [***] of the [***] for such trials and the
[***] and [***] of [***] and [***] from [***] Trials and [***] Trials for the
Products, and (ii) Amgen will [***] to [***] in [***] with the [***] and the
[***] for the [***] Trials and [***] Trials for the Products; provided that, as
between the Parties, Amgen will [***] with respect to any such activities, and
Micromet will [***] Amgen’s [***] with respect thereto.  The Parties anticipate
that Micromet’s support for such clinical activities would not [***], unless
otherwise recommended by the JPT and approved by the JSC.
 
(b)           Other Clinical Trials.  Amgen will draft the clinical protocols
for all other clinical trials of Products, and will be fully responsible for the
performance of such trials in accordance with the Development Plan.  Micromet
will continue to provide assistance, as Amgen may reasonably request from time
to time and subject to oversight and final decision-making authority by Amgen,
for such clinical activities.
 
(c)           [***] Studies.  Notwithstanding the foregoing, Amgen may, at its
discretion, supply Product to [***] for [***] clinical trials for the Products,
and Amgen may review and approve the clinical protocols for such studies in its
discretion; provided, that any [***] Trials or [***] Trials for Product will be
subject to the applicable terms of Section 4.2.4(a) above.
 
4.3          Diligence in Development. Micromet will diligently perform its
obligations to generate BiTE Antibodies binding to the Collaboration Target, and
to perform the activities assigned to it in the Development Plan.  Amgen will
use Commercially Reasonable Efforts to develop one or more Products and obtain
Marketing Approval for such Product(s) throughout the Territory and to perform
the activities assigned to it in the Development Plan; provided, that, for the
avoidance of doubt, Amgen will have no obligation to seek to develop or obtain
Marketing Approval for any Product in any country in which it would not be
Commercially Reasonable to do so. All efforts of a Party’s Affiliates,
sublicensees and Service Providers will be considered efforts of such Party for
the purpose of determining such Party’s compliance with its obligations under
this Section 4.3.
 
4.4          Reports.  During the [***], each Party will provide through the JPT
regular reports to the JSC detailing its development activities under the
Development Plan and the results of such activities.  After completion of the
[***] or the [***] of the JSC, Amgen will provide to Micromet [***] written
progress reports during each [***] with a summary of [***] in the [***] of the
[***] of the Product and a summary of the [***] for the Product.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
23

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

4.5          Use of Service Providers.  Subject to this Section 4.5, each Party
may perform any of its obligations under the Development Plan through Third
Party service providers such as contract research organizations, consultants or
other independent contractors (each a “Service Provider”).  The Party engaging a
Service Provider will be responsible for conducting such qualification and
compliance audits as may be required under GxP regulations prior to and during
the engagement of such Service Provider.  During the duration of the [***], each
Party will inform the other Party of the identity, and the nature of services
provided by the Service Providers used by such Party, and the Party using a
Service Provider will remain responsible to the other Party for the work
performed by the Service Provider.  Each Party will ensure that (a) such Service
Providers are bound in writing by obligations of confidentiality and non-use
regarding Confidential Information that are substantially the same as or more
stringent than those undertaken by the Parties pursuant to Article 11 hereof and
the provisions on intellectual property ownership hereunder and (b) the
agreement with such Service Providers contains customary terms providing for the
assignment to such Party of all intellectual property developed in the course of
performing the services for such Party.
 
4.6          Compliance.  Each Party will conduct its respective research and
development activities under the Development Plan with respect to a Product in
good scientific manner, and in compliance in all material respects with all
requirements of Applicable Law.
 
5.           Commercialization
 
5.1         Commercialization.  Except as described in Section 5.2 and as
otherwise provided in this Agreement, (a) Amgen will be solely responsible for
and bear all costs and expenses associated with the Commercialization of
Products in the Territory and (b) Amgen will be responsible for all aspects of
the Commercialization of the Products in the Territory, including booking sales
and distribution and performance of related services, handling all aspects of
order processing, invoicing and collection, inventory and receivables, and
providing customer support, including handling medical queries.  Amgen will
provide the JSC (or, if there is no JSC, then Micromet’s Alliance Manager) with
its annual commercialization plan for a Product that is generated by Amgen
consistent with its regular business practices for Commercializing similar
products.  Amgen will review and discuss such plan with Micromet through the JSC
or Alliance Manager, as applicable.
 
5.2         Limited [***].  If Amgen pursues the development of a Product for
the [***] of [***], then Micromet will have a [***] to [***] any such Product in
the [***] in [***] jointly with Amgen pursuant to a [***] describing the [***]
activities of the Parties for the Product in [***] (the “[***]”), which will be
[***] in [***] in accordance with, and incorporate the terms set forth in,
Exhibit I.  Notwithstanding the foregoing, if Micromet [***] a [***] then the
[***] to Micromet under this Section 5.2, and any [***], will [***] and [***] of
[***] or [***], unless Amgen elects otherwise in writing.
 
5.3         Diligence in Commercialization. Amgen will use Commercially
Reasonable Efforts to Commercialize Products in the Territory following receipt
of Marketing Approval therefor in the applicable country in the Territory.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
24

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

5.4         Branding, Trademarks, Trade Dress and Logos. As between the Parties,
Amgen will solely own, and will be solely responsible for selecting, the
trademark used to identify any Product that will be Commercialized in the
Territory pursuant to this Agreement.  Amgen will oversee the filing,
prosecution and maintenance of all trademark registrations for Products in the
Territory, and Amgen will be responsible for the payment of any and all costs
relating to such filing, prosecution, and maintenance.  Amgen will have sole
responsibility for, and will be the sole owner of, all trade dress, logos,
slogans, and designs used on and in connection with any Product that will be
Commercialized in the Territory pursuant to this Agreement.
 
6.           Regulatory Matters
 
6.1         Regulatory Filings. As between the Parties, Amgen will be
responsible for the preparation, filing, prosecution and maintenance of any
Regulatory Filings for Products and, except as provided in Section 4.2.4(c),
will be the sponsor of any clinical trials for Products.  Amgen will provide
Micromet with copies of any Regulatory Authority annual reports and investigator
brochures for Products, as well as any updates to such reports or brochures, all
of which shall be deemed Amgen’s Confidential Information (except for any
Micromet Confidential Information embedded therein).  Micromet will assist
Amgen, at Amgen’s reasonable request and as may be reasonably necessary, in the
preparation of Regulatory Filings, including providing necessary documents or
other materials or information as reasonably requested by Amgen in connection
with such Regulatory Filings.  Amgen will reimburse Micromet at the FTE Rate and
for all Out-of-Pocket Costs for such regulatory support activities performed by
Micromet at Amgen’s request.  All Regulatory Filings (including all INDs and
Marketing Approvals) relating to the Products will be owned by, and will be the
sole property and held in the name of Amgen or its designated Affiliate,
sublicensee or designee.  Except as provided in Section 4.2.4(c), as between the
Parties, Amgen will be responsible for and control the performance of each
clinical trial for Products, including but not limited to any decisions relating
to the safety of any subjects participating in such clinical trial.
 
6.2         Communications and Meetings with Regulatory Authorities.  As between
the Parties, Amgen will be responsible for any communications with the
Regulatory Authorities occurring or required in connection with obtaining or
maintaining any Regulatory Filings or Marketing Approvals for a Product.  Amgen
will promptly provide Micromet with copies of all written or electronic
correspondence received from Regulatory Authorities dealing with [***] to the
[***] or [***], as well as any critical agency correspondence related to
Products, and where possible will provide Micromet with a reasonable opportunity
to provide comments on any responses to such Regulatory Authorities with respect
to such correspondence.  In addition, Amgen will promptly notify Micromet in
writing and in advance of any meeting with any Regulatory Authority in the U.S.
or the EU dealing with [***] to the [***] or [***], and Micromet may, at its own
expense, have an employee or consultant participate in such meeting as a silent
observer.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
25

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

6.3         Clinical Safety and Pharmacovigilance Matters.  As between the
Parties, Amgen will be responsible for handling, recording and reporting adverse
events arising in clinical trials of the Product, and will establish the
standard operating procedures implementing the requirements under Applicable
Law.  Amgen will establish and maintain the global safety database (including
the core data sheet) for each Product.  Amgen will provide Micromet with prompt
notice of any adverse events related to the Products, the [***] or the [***] or
otherwise applicable to [***], as well as copies of any reportable adverse
events related thereto, in each case prior to submission of such reports to the
applicable Regulatory Authority, if practicable, but at the latest promptly
following such submission (including any exigent submissions, which Amgen will
submit in accordance with Applicable Law).  Upon Micromet’s request, Amgen will
discuss any such adverse events related to the [***], the [***], or otherwise
applicable to [***] with Micromet.
 
6.4         Audits and Inspections.  Each Party will promptly inform the other
Party of any inspections of its facilities or records relating to the
development or manufacture of a Product that are planned to be performed by any
Regulatory Authorities, in each case to the extent related or pertaining to a
Product.  The Party to be inspected will take all reasonable measures in
accordance with standard industry practice to prepare for such inspections.  The
other Party will have the right to have an employee or consultant attend such
inspections as a silent observer.
 
6.5          Recalls and Voluntary Withdrawals. Amgen will have the right and
obligation, at its expense, to control any Product recall, field correction, or
withdrawal of any Product in the Territory; provided, however, that Amgen will
promptly notify Micromet of any recall action being considered, and where
practicable, consider the views of Micromet prior to taking any recall action.
 
6.6          Regulatory Records.  All activities performed by or on behalf of a
Party under the Development Plan will be completely and accurately recorded and
summarized in reports, in sufficient detail and in good scientific manner, and
as required by applicable GxP regulations and Applicable Law.  Each Party will
maintain, or cause to be maintained, for at least [***] ([***])[***] after the
termination of this Agreement, or for such longer period as may be required by
Applicable Law, complete and accurate records of its respective development
activities with respect to a Product, including the drug master file, Product
recalls, and other records made in connection with or filed with any Regulatory
Authority.
 
6.7          Exigent Circumstances.  Notwithstanding any of the foregoing,
nothing in this Article 6 will prevent Amgen from taking any reasonable action
under exigent circumstances (including with respect to patient safety).
 
7.           Intellectual Property Matters
 
7.1          Inventorship.  Inventorship with respect to any invention or
discovery that is or may be patentable and is made pursuant to activities
conducted pursuant to this Agreement will be determined in accordance with
applicable law in the United States regardless of where and when such invention
or discovery occurs.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
26

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

7.2         Ownership.  Micromet will own all right, title and interest in and
to any [***] Technology, [***] Technology, [***] Technology, and Micromet’s
rights and interest in [***] Technology.  Amgen will own all right, title and
interest in and to any [***] Technology, [***] Technology and Amgen’s rights and
interest in [***] Technology.  Micromet and Amgen will each [***] an [***] in
any [***] Technology, without obligation to account to the other for the
exploitation thereof or to seek consent of the other for the practice of, grant
of any licenses under, or enforcement of rights in, [***] Technology (and each
Party hereby waives any requirement under Applicable Law of any country to
obtain such consent or to account for profits with respect to such [***]
Technology), except as expressly limited by the terms of this Agreement.
 
7.3         Disclosure of Know-How.  Each [***] during the performance of the
[***], (a) the Parties will provide an update regarding Know-How developed under
the [***] since the last such update in written reports provided to the JPT or
the JSC, and (b) following Amgen’s reasonable request in the JPT or Micromet’s
determination, in each case where such Know-How would be [***] under this
Agreement, Micromet will provide Amgen with [***] that is [***] under this
Agreement.   Following the completion of the [***], the Parties will disclose
Know-How licensed to the other Party under this Agreement in annual reports to
the JSC.  If such Know-How is a patentable invention, the owner thereof pursuant
to Section 7.2 above may withhold the disclosure to the other Party until after
the filing of a patent application claiming such invention.
 
7.4          Filing, Prosecution and Maintenance of Patents.
 
7.4.1      [***] Technology.  With respect to any Patent application within the
[***] Technology, [***] Technology or [***] Technology, the Parties will
cooperate to determine inventorship as set forth in Section 7.1, and as
applicable, to develop a strategy to [***] relating to the [***] from [***]
relating to [***], and to [***] accordingly.

 
7.4.2      [***] Patents.  Subject to the terms of this Article 7, Micromet will
file, prosecute, defend and maintain (including the filing of any extension or
supplementary protection certificate) at its cost any [***] Patents, in its
discretion and in accordance with its business practices.  Micromet will provide
Amgen with an update of the filing, prosecution and maintenance status for each
of the [***] Patents within the [***] Technology and [***] Technology on a
periodic basis, and will use reasonable efforts to consult and cooperate with
Amgen with respect to the filing, prosecution and maintenance of such Patents,
and to allow Amgen a reasonable opportunity for review and comment before such
filings are due.  Micromet will give reasonable consideration to any suggestions
or recommendations of Amgen concerning the preparation, filing, prosecution,
defense and maintenance of such Patents.  Micromet will file and maintain the
[***] Patents, at [***] and [***], in the [***] specified in [***], and in any
other [***] requested by Amgen.  Amgen will reimburse Micromet for costs and
expenses incurred for filing and maintenance of Patents in [***] requested by
Amgen; provided, that in the event Micromet receives reimbursement from any
other Third Party licensee [***] then it will reasonably allocate the
reimbursement [***] between Amgen and any such other licensee(s).  If Micromet
desires to [***] the [***] of a [***] Patent within the [***] Technology or the
[***] Technology (other than cases where Micromet intends to [***] such [***]
Patent with a [***] that [***] the [***]), then it will [***] Amgen thereof in
writing with [***] to reasonably enable Amgen to [***] the [***] or [***] of
such Patent (but in no event [***] ([***])[***] prior to the next [***] for any
[***] that may be [***] with respect to such Patent with the U.S. Patent and
Trademark Office or any non-U.S. patent office), at [***] cost; provided, that
Amgen will not [***] any such [***] Patent in a [***] that is [***] to the other
[***] Patents.  In its prosecution of [***] Patents filed after the Effective
Date, Micromet will use reasonable efforts to [***] relating to the Products
from [***] relating to [***].  Micromet further [***] to file Patents that [***]
to the [***] (or, during the [***], to the [***]), without Amgen’s prior written
consent (not to be unreasonably withheld).

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
27

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

7.4.3       [***] Patents.  Amgen will have the first right, but not the
obligation, to file, prosecute, defend and maintain at its cost any [***]
Patents.  Amgen will reasonably inform Micromet and consult with Micromet
regarding the filing, prosecution, defense and maintenance of [***] Patents and
will give reasonable consideration to any suggestions or recommendations of
Micromet concerning the preparation, filing, prosecution, defense and
maintenance of such Patents.  If Amgen desires to [***] the [***] of a [***]
Patent or elects [***] a [***] Patent within the [***] Technology, the [***]
Technology or the [***] Technology (other than cases where Amgen intends to
[***] such [***] Patent with a [***] that [***] the [***]), then it will [***]
Micromet thereof in writing with [***] to reasonably enable Micromet to [***]
the [***] or [***] of such Patent (but in no event [***] ([***])[***] prior to
the next [***] for any [***] that may be [***] with respect to such Patent with
the U.S. Patent and Trademark Office or any Non-U.S. patent office), at [***]
cost; provided, that Micromet will not [***] any such [***] Patent in a [***]
that is [***] to the other [***] Patents.  In its prosecution of [***] Patents
filed after the Effective Date, Amgen will use reasonable efforts to [***]
relating to the Products from [***] relating to [***].
 
7.4.4       Cooperation.  Each [***] during the Term, each Party will provide
the other Party with summaries (or copies as reasonably requested) of patent
applications, office actions (including restriction requirements) and
substantive correspondence with the applicable patent office for such Patents
and made during such preceding [***].  Each Party will cooperate with the other
Party, execute all lawful papers and instruments and make all rightful oaths and
declarations as may be necessary in the preparation, prosecution and maintenance
of all Patents and other filings in accordance with this Section 7.4.
 
7.5          Enforcement of Patents.
 
7.5.1       Notice.  If either Party learns of any actual or threatened
infringement or misappropriation of any [***] Patent or [***] Patent by a Third
Party’s Exploitation of a [***] a [***] that [***] to a [***] with respect to
which this Agreement has not previously terminated, including the filing of any
certification pursuant to the Biosimilar Act or any equivalent thereof (any of
the foregoing, an “Infringement”), it will promptly notify the other Party
thereof including available evidence of such Infringement.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
28

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

7.5.2      Enforcement Actions.
 
(a)         [***] Patents.
 
(i)           Amgen will have the first right (but not the obligation) to take
appropriate steps to remove the Infringement of the [***] Patents, including by
initiation, prosecution and control at its own expense of any suit, proceeding
or other legal action by counsel of its own choice.
 
(ii)          Micromet will have the right, at its own expense, to be
represented in any such action by counsel of its own choice.  In addition,
Micromet agrees to be joined as party plaintiff if necessary to prosecute the
action or proceeding and to give Amgen reasonable assistance and authority to
file and prosecute the suit; provided, however, that Micromet will not be
required to transfer any right, title or interest in or to any property to Amgen
or any other party to confer standing on Amgen hereunder.
 
(b)         [***] Patents.
 
(i)           Micromet will have the first right (but not the obligation) to
take appropriate steps to remove the Infringement of the [***] Patents,
including, by initiation, prosecution and control at its own expense of any
suit, proceeding or other legal action by counsel of its own choice.
 
(ii)          If Micromet fails to bring an action or proceeding to remove the
Infringement pursuant to Section 7.5.2(b)(i) (only in the case that the Patent
at issue is [***] for the [***] of a [***]) within [***] ([***]) days (or [***]
([***]) days in the case of an action brought under the Biosimilar Act or within
the time frame of any other relevant regulatory or statutory framework that may
govern) of learning of the Infringement (or, if sooner, [***] ([***]) days
before the time limit, if any, set forth in the relevant laws and regulations
for the filing of such actions), or earlier notifies Amgen in writing of its
intent not to bring such action or proceeding, then Amgen will have the right
(but not the obligation) to bring any such action or proceeding by counsel of
its own choice; provided, however, that Micromet will have the right to approve
in writing any settlement of any claim, suit or action involving its Patents
that admits the invalidity or unenforceability of its Patents or imposes on
Micromet restrictions or obligations, such approval not to be unreasonably
withheld or delayed.
 
(iii)         The Party that is not the plaintiff in an action brought by the
other Party pursuant to this Section 7.5.2(b) will have the right, at its own
expense, to be represented in any such action by counsel of its own choice.  In
addition, such Party agrees to be joined as party plaintiff if necessary to
prosecute the action or proceeding and to give the other Party reasonable
assistance and authority to file and prosecute the suit; provided, however, that
neither Party will be required to transfer any right, title or interest in or to
any property to the other Party or any other party to confer standing on a Party
hereunder.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
29

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

 (c)         Recoveries.  Any settlements, damages or other monetary awards (the
“Recovery”) recovered by a Party in an action pursuant to this Section 7.5.2
will be allocated first to the costs and expenses of the Party bringing suit,
and second to the costs and expenses (if any) of the other Party, with any
remaining amounts (if any) to be allocated as follows:
 
(i)         If Amgen pursued such action, the Recovery will be deemed to be Net
Sales and Amgen will pay a royalty to Micromet as provided in Section 9.4.
 
(ii)        If Micromet pursued such action, then (A) to the extent the Recovery
is based on the damages incurred by Micromet, such Recovery will be retained by
Micromet and (B) to the extent the Recovery is based on damages incurred by
Amgen, such Recovery will be deemed to be Net Sales, and Micromet will pay to
Amgen the portion of such Recovery based on the damages incurred by Amgen to
Amgen after deducting the royalty due to Micromet thereon pursuant to Section
9.4.
 
7.6         Defense and Settlement of Third Party Claims.  Each Party will
promptly notify the other in writing of any allegation by a Third Party that the
activity of either Party pursuant to this Agreement infringes or may infringe
the intellectual property rights of such Third Party.  Micromet will have the
sole right to control any defense of any such claim involving alleged
infringement of Third Party rights by Micromet’s activities at its own expense
and by counsel of its own choice, and Amgen will have the right, at its own
expense, to be represented in any such action by counsel of its own
choice.  Amgen will have the sole right to control any defense of any such claim
involving alleged infringement of Third Party rights by Amgen’s activities at
its own expense and by counsel of its own choice, and Micromet will have the
right, at its own expense, to be represented in any such action by counsel of
its own choice.  Neither Party will have the right to settle any patent
infringement litigation under this Section 7.6 in a manner that admits the
invalidity or unenforceability of the other Party’s Patents or imposes on the
other Party restrictions or obligations, without the written consent of such
other Party (which consent will not be unreasonably withheld or delayed).
 
7.7          Patent Term Extensions.  The Parties will cooperate in obtaining
patent term restorations, supplemental protection certificates and the
equivalents of each of the foregoing, and other forms of patent term extensions
(any of the foregoing, a “Patent Term Extension”) for Products with respect to
the [***] Patents in any country or region where applicable.  Amgen will not
have the right to seek any Patent Term Extension of any [***] Patent without
Micromet’s prior written consent; provided, that, at Amgen’s reasonable request,
Micromet will seek a Patent Term Extension for [***] Patents within the [***]
Technology or [***] Technology unless such extension would, in Micromet’s
good-faith discretion, have a detrimental effect on the availability of a Patent
Term Extension for [***] under [***] or [***] by Micromet or its
licensees.  Micromet will not, without Amgen’s prior written consent, seek any
Patent Term Extension of (a) a [***] Patent for [***], or (b) a [***] Patent for
[***].

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
30

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

7.8         [***].  The Parties acknowledge and agree that the performance of
the research and development activities contemplated under this Agreement is a
[***] conducted by and between the Parties and through the JSC and JPT in
accordance with the terms and conditions set forth herein and that this
Agreement is a [***] under [***].  The Parties further agree to [***] to avail
themselves and each other of the provisions of [***] as amended through the
[***] on [***].
 
7.9         Compensation of Micromet Employees.  The Parties acknowledge and
agree that Micromet and employees of Micromet are each subject to the German Act
on Employees’ Inventions (Arbeitnehmererfindergesetz) under which Micromet may
have an obligation to compensate its employees if they are inventors of [***]
Technology, [***] Technology, [***] Technology, or [***] Technology.  Micromet
will pay any such compensation to its employees who are inventors of such
technology at its own cost and expense and Amgen will have no liability with
respect thereto.
 
8.           License Grants
 
8.1         License Grants by Micromet.  Subject to the terms and conditions set
forth in this Agreement, Micromet grants to Amgen an exclusive, royalty-bearing
license or sublicense (as applicable) under the Licensed Technology to develop,
have developed, make, have made, use, offer for sale, sell, have sold, import,
export, Commercialize and otherwise Exploit Products in the Field in the
Territory.  To the extent that Micromet Controls any Licensed Technology on a
non-exclusive basis or such Control is subject to other limitations, Micromet
grants to Amgen the foregoing license to the greatest extent that it Controls
such Licensed Technology.
 
8.2         [***].  Amgen acknowledges and agrees that it has received a copy of
each [***], and that the sublicense granted in Section 8.1 under any [***]
Technology is subject to the terms of the applicable [***] and any [***].  Amgen
covenants not to take or fail to take any action that violates the terms of such
[***] or any [***] applicable to sublicensees, or that would cause Micromet to
be in breach of any of the terms of the [***] or any [***], other than the
payments due pursuant to such [***] which remain an express obligation of
Micromet as provided in Section 9.5.1.  Notwithstanding the foregoing, Micromet
will immediately notify Amgen if Micromet receives written notice alleging a
material breach of any of the [***] or any [***] and Amgen will have the right
to cure on behalf of Micromet any such breach that might adversely affect
Amgen’s rights hereunder.  Micromet covenants not to take or fail to take any
action to limit or to deny the sublicense granted in Section 8.1 under any [***]
Technology.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
31

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

8.3          [***] Technology.
 
8.3.1       From time to time during the Term, but no less than [***], Micromet
will disclose to Amgen all [***] Technology conceived, generated, in-licensed or
otherwise acquired since the last such disclosure in such detail as reasonably
required for Amgen to determine its interest in seeking a license pursuant to
this Section 8.3.1.  If Amgen desires to obtain a license under any [***]
Technology so disclosed, then Amgen will provide Micromet with written notice of
such determination.
 
8.3.2       If such [***] Technology was [***] by employees, agents or Service
Providers of [***], then the Parties will negotiate in good faith the [***] for
including such [***] Technology in the [***] Technology, taking into
consideration [***] for [***] in the generation of such [***] Technology.
 
8.3.3       If such [***] Technology was [***] or [***] to [***] by a [***],
then the Parties will negotiate in good faith the [***] for including such [***]
Technology in the [***] Technology, taking into consideration (a) for technology
[***] by [***], a [***], based on the [***] of such technology for [***], among
other commercially relevant factors, [***] for such technology and [***] by
[***] to its [***] resulting from the [***] of a [***] to Amgen for the [***] or
[***] of [***] (it being understood that, subject to Section 9.5.1 and the last
sentence of this Section 8.3.3, [***] will be [***] for all [***] to a [***] to
the extent arising from the [***] to [***] or [***] practice of the [***] to
[***] to such [***] Technology), and (b) for technology [***] by [***], a [***]
of such [***] based on the [***] of such technology for [***], among other
commercially relevant factors.  Any license granted to Amgen will be subject to
the terms and conditions of any [***] agreement under which such [***]
Technology is [***], and Micromet agrees to [***] such terms and conditions to
Amgen prior to the Parties’ first execution of any agreement under this Section
8.3.3 reflecting the terms of [***] for such [***] Technology.
 
8.3.4       If the Parties fail to reach an agreement on the [***] for including
[***] Technology in the Licensed Technology within [***] ([***])[***] of Amgen’s
notice, the procedure described in Section 18.4 will apply.
 
8.4          Access to [***] Technology.
 
8.4.1       Promptly after the Effective Date, Micromet will disclose to Amgen
all [***] Technology existing as of the Effective Date that is available for a
license to Amgen in such detail (and including the financial terms thereof) as
is reasonably required for Amgen to determine its interest in seeking a license
thereunder pursuant to this Section 8.4.1.  From time to time during the Term,
but at least [***], Micromet will disclose to Amgen all [***] Technology
in-licensed or otherwise acquired since the last such update.  Amgen
acknowledges that it only may receive a right to license Patents and Know-How of
a [***] that, treating such Patent or Know-How as [***] Technology hereunder,
would be eligible for license to the particular [***] under [***] terms and
conditions (including [***]) in all material respects as further described
below.  If Amgen desires to obtain a license under such Patents or Know-How,
then Amgen will provide Micromet with written notice thereof and this Agreement
will be amended to include such [***] Technology in the [***] Technology and
licensed to Amgen under the terms of this Agreement.  The terms of such license,
including [***], will be determined at the time and would be [***] with the
[***] set of [***] applied by the relevant [***] to such [***] Technology, on
the one hand, and Amgen to [***] Technology that is [***] to such [***]
Technology, on the other hand.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
32

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

8.4.2       Subject to Section 9.5.1, Amgen will be responsible for all
payments, if any, due to a [***] on account of any sublicense to Amgen of any
[***] Technology to the extent arising from Amgen’s practice of the license
granted to Amgen pursuant to Section 8.4.1, to the extent such payments were
disclosed to Amgen in accordance with Section 8.4.1 above.  Each such license
only will be granted to the extent that Amgen would not restrict the license of
[***] Technology to such [***] under Section 8.6.2 or 8.6.3, as the case may be.
 
8.5         Sublicensing by Amgen.  Subject to the terms and conditions of this
Agreement, Amgen will have the right to sublicense (with the right to grant
further sublicenses through multiple tiers) all or part of the rights granted
under Section 8.1:  (a) at any time, to an Affiliate but only for such period of
time as such entity remains an Affiliate of Amgen, or to a Service Provider
solely to the extent necessary for the performance of any contract research,
contract manufacturing or other similar service relating to this Agreement, (b)
at any time, if such sublicense is to a Third Party (other than a Service
Provider) for the development or Commercialization of a Product [***] other than
a [***], and (c) solely following initiation of the first [***] for such
Product, if such sublicense is to a Third Party (other than a Service Provider)
for the development or Commercialization of a Product [***]; provided, in each
case and as a condition of such sublicense, that (i) such sublicensee will have
sufficient financial and other resources and expertise in the development and/or
commercialization (as applicable) of related pharmaceutical products, (ii) Amgen
remains responsible to Micromet for the performance of Amgen’s obligations under
this Agreement (either directly by Amgen or by a sublicensee), and (iii) such
sublicensee agrees to be bound by the applicable terms and conditions contained
in this Agreement.  In addition, Amgen will use Commercially Reasonable efforts
to obtain rights to any data, materials, reports, information, intellectual
property and other Know-How generated by its sublicensees sufficient to permit
Amgen to provide Micromet with the copies, licenses and other rights described
under Section 14.1.  If Amgen is unable to obtain such rights, then, prior to
executing the applicable sublicense agreement, Amgen will notify Micromet and
the Parties will discuss in good faith the scope of reversion rights to be
obtained from such sublicensee.
 
8.6          License Grants by Amgen.
 
8.6.1       Unblocking of Collaboration Activities.  Subject to the terms and
conditions set forth in this Agreement, Amgen grants to Micromet a
non-exclusive, worldwide, royalty-free license under any [***] Technology and
[***] Technology [***] for Micromet solely to conduct its obligations under the
Development Plan.  Such license will be sublicenseable solely to Affiliates of
Micromet and Service Providers for the provision of services to Micromet to
allow Micromet to conduct its obligations under the Development Plan.  Amgen
further grants to Micromet a non-exclusive, worldwide, royalty-free license of
all rights in the Licensed Technology granted to Amgen pursuant to Section 8.1,
solely to conduct Micromet’s obligations under the Development Plan.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
33

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

8.6.2      [***] Technology.  Subject to the terms and conditions set forth in
this Agreement, Amgen hereby grants to Micromet a worldwide, non-exclusive,
irrevocable (except as provided in this Section 8.6.2), fully-paid, royalty-free
license (with the right to sublicense to [***] as described in Section 8.6.6)
under the [***] Technology to Exploit BiTE Antibodies (other than those binding
to a Collaboration Target (or, during the Feasibility Phase, to a Feasibility
Target)).  In the event of a material breach by Micromet of the license granted
to Micromet under this Section 8.6.2 or Micromet’s practice thereof, or
Micromet’s obligations under Article 11 with respect to [***] Technology, (a) if
such breach is limited to a particular [***] or [***], then Amgen will have the
right to terminate such license with respect to the [***] and/or [***] to which
such material breach relates, and (b) if such breach relates to such license in
general, then Amgen will have the right to terminate such license with respect
to any [***] and [***], except to the extent such [***] Technology is, as of the
effective date of such termination, [***] or [***] products being developed
under [***] then being conducted by or on behalf of Micromet or such [***];
provided, that Micromet may dispute such material breach in accordance with the
procedures described in Section 13.3.2 (i.e., [***] of the [***] of such
dispute, and the [***] to [***] in lieu of [***]).
 
8.6.3      Access to Other [***] Technology.
 
(a)           From time to time during the Term, but at least [***], Amgen will
disclose to Micromet all Patents in the [***] Technology conceived or generated
since the last such update that Amgen [***] in its [***] a license to Micromet,
in such detail as is reasonably required for Micromet to determine its interest
in seeking a license thereunder pursuant to this Section 8.6.3.
 
(b)           If Micromet desires to obtain a license under such Patents
described in 8.6.3(a), then Micromet will provide Amgen with written notice, and
the Parties will negotiate in good faith for a reasonable period of time the
terms (including sublicense terms) of a non-exclusive, royalty-bearing license
under the respective Patents in the [***] Technology; provided, that in no event
will Amgen be obligated to negotiate such terms for longer than a period of
[***] ([***])[***] after receipt of such notice from Micromet.
 
8.6.4       Limited License to [***] Technology.  Amgen hereby grants to
Micromet a non-exclusive, worldwide, royalty-free license, solely for the
Exploitation of BiTE Antibodies (other than Products), to those claims of all
Patents [***] by [***] with a [***] on or after [***], to the extent that they
claim and would be infringed by the [***] (including any [***] or [***]
components thereof) as practiced by Micromet on or before the Effective Date, in
part or in whole, and are derived from Know-How or Confidential Information
provided to Amgen by Micromet in connection with the negotiation or performance
of this Agreement.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
34

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

8.6.5       [***] Technology.
 
(a)           With respect to any Patents relating to [***] Technology that
Amgen or any of its Affiliates generates pursuant to activities conducted under
this Agreement prior to the completion of the [***], Amgen hereby grants to
Micromet a worldwide, non-exclusive, irrevocable (except as provided in this
Section 8.6.5 and Section 18.5), fully-paid, royalty-free license (with the
right to sublicense to [***] as described in Section 8.6.6)  under such Patents
to the extent they claim [***] Technology (as defined below) that is [***] for
[***] of [***] (other than those binding to a Collaboration Target (or, during
the Feasibility Phase, to a Feasibility Target)).  Amgen will provide to
Micromet a copy of any such Patent application upon publication thereof,
together with a notice of any such [***] Technology claimed therein that Amgen
determines in good faith [***], or has not [***] within [***] ([***])[***]
following the publication of such Patent application (and in such case does not
have a [***] and [***] in place [***]), in the [***] of a Product (“[***]
Technology”).  From time to time thereafter, Amgen will notify Micromet if Amgen
[***] of any [***] Technology claimed in such Patents and does not [***] the
[***], and such [***] Technology will be deemed [***] Technology.
 
(b)           In the event of a material breach by Micromet of this Agreement
that relates to the license granted to Micromet under this Section 8.6.5 or
Micromet’s practice thereof, or Micromet’s obligations under Article 11, Amgen
will have the right to terminate such license; provided, that Micromet may
dispute such material breach in accordance with the procedures described in
Section 13.3.2 (i.e., [***] of the [***] of such dispute, and the [***] to [***]
in lieu of [***]).
 
8.6.6       Sublicensing by Micromet.  Micromet will have the right to grant
sublicenses (with the right to grant further sublicenses through multiple tiers)
under the licenses granted under Sections 8.6.2, 8.6.3, 8.6.4 and 8.6.5, as
applicable, to [***]; provided, in each case and as a condition of such
sublicense, that: (a) with respect to [***] Technology, such sublicense would be
granted to each [***] on terms consistent with the [***] (including [***])
applied by Amgen, on the one hand, to such [***] Technology and by the relevant
[***], on the other hand, to [***] Technology Controlled by such [***] that is
[***] to the applicable [***] Technology (taking into account any restrictions
on licensing to Amgen under the agreement between Micromet and the [***]), (b)
Micromet remains responsible to Amgen for the performance of Micromet’s
obligations under this Agreement (either directly by Micromet or by Micromet’s
sublicensee), (c) such sublicensee agrees to be bound by the applicable terms
and conditions contained in this Agreement, and (d) such sublicensee has
sufficient financial and other resources and expertise in the development and/or
commercialization (as applicable) of related pharmaceutical products.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
35

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

8.7          Retained Rights.
 
8.7.1       Amgen Intellectual Property Rights.  Except as expressly set forth
in this Agreement, nothing in this Agreement will grant to Micromet any right,
title or interest in and to the intellectual property rights of Amgen or its
Affiliates (either expressly or by implication or estoppel), and Amgen reserves
all rights to the intellectual property rights Controlled by Amgen (including
the [***] Technology and [***] Technology) and reserves the right to utilize or
allow Third Parties to practice such rights.
 
8.7.2       Micromet Intellectual Property Rights. Except as expressly set forth
in this Agreement, nothing in this Agreement will grant to Amgen any right,
title or interest in and to the intellectual property rights of Micromet or its
Affiliates (either expressly or by implication or estoppel), and Micromet
reserves all rights to the intellectual property Controlled by Micromet and its
Affiliates (including the [***] Technology and [***] Technology) and reserves
the right to utilize or allow Third Parties to practice such rights.
 
8.7.3       Limitation on Use of Materials.  Each Party hereby covenants and
agrees not to use any Antibodies or other materials provided to such Party by
the other Party under this Agreement (or any derivative materials thereof) for
any purpose other than the performance of activities under this Agreement, to
the extent such Antibodies or other materials comprise Know-How that is
Confidential Information of the other Party.
 
8.8          Exclusivity.
 
8.8.1       During the Term, each Party will not, and will cause its Affiliates
not to, either directly or through any Third Party, research, clinically
develop, make, have made, use, offer for sale, sell, have sold, import,
Commercialize or otherwise Exploit within the Territory any [***] to a [***] (a
“Competing Product”), nor grant any license or other rights to a Third Party to
conduct any of the foregoing within the Territory.  Prior to the selection of a
[***] the foregoing obligation will extend to the [***].  For clarity, research
on the basic biology associated with the [***] or research by Micromet on the
[***] generally (excluding any specific [***] or [***]) would not be a violation
of this Section 8.8.1.
 
8.8.2       In the event that any Party engages in a [***] (defined below) with
respect to a Third Party resulting in such Party controlling a [***], then the
terms of Section 8.8.1 will not apply to, or in any way limit or restrict, by or
on behalf of a Party or its Affiliates, the development, use, manufacture,
marketing, sale, promotion, Commercialization or other Exploitation of any [***]
controlled by such Third Party or its Affiliates that, as of the date of
consummation of such [***], was the subject of an [***] program (at least
including [***] testing or other [***] studies) or [***] program, or was being
[***] by such Third Party.  In such case, the Parties will mutually agree upon
reasonable safeguards to protect sensitive information regarding any [***]
(including, by way of example, a prohibition on non-executive [***] personnel
supporting [***], the creation of internal procedures to limit the flow of
information between project team members, etc.).

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
36

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

8.8.3      As used in this Section 8.8, “[***]” means (a) a [***] of a Party
where the [***] of the [***] and its [***], considered in the aggregate,
consists of [***] or [***] of [***] prior to the consummation of such [***], and
(b) a [***] of a Third Party where the [***] of the [***] and its [***],
considered in the aggregate, consists of [***] or [***] of [***] prior to the
consummation of such [***].
 
8.9          Consequences of Patent Challenge.
 
8.9.1      If Amgen or any of its Affiliates directly, or indirectly through
assistance granted to a Third Party (Amgen, its Affiliate or any such Third
Party in the context of a Patent Challenge, a “Patent Challenger”), commences
any Patent Challenge, then Micromet will have the right, by written notice to
Amgen, to terminate Amgen’s license under this Agreement to the Patent(s) at
issue.  For purposes of this Section 8.9, “Patent Challenge” means any legal
action, including interference or opposition proceedings, to challenge the
validity or enforceability of, or oppose any extension of or the grant of a
supplementary protection certificate with respect to, any Patent within the
Licensed Technology; provided, however, that none of the following will
constitute a “Patent Challenge”: (a) a Patent Challenger’s assertion that (i)
any invention or discovery claimed by a Patent filed by or on behalf of Micromet
as a Patent claiming [***] Technology, [***] Technology, [***] Technology, [***]
Technology or [***] constituted an invention or discovery of a Patent
Challenger, or (ii) any invention or discovery claimed by a Patent filed by or
on behalf of Micromet as a Patent claiming [***] Technology constituted [***]
Technology; (b) any claim made by a Patent Challenger as a defense in any
lawsuit or administrative proceeding brought in connection with the Patent(s) at
issue; and (c) any good faith Dispute initiated in accordance with Section
18.4.3(b) by Amgen regarding the validity of one or more claims of any Patents
within the [***] Technology that, [***], would [***] the [***] of [***] to
Micromet under this Agreement (as described in such Section 18.4.3(b)).
 
8.9.2       Amgen will include provisions in all agreements granting sublicenses
of Amgen’s rights hereunder providing that if the sublicensee or any of its
Affiliates undertakes a Patent Challenge (substituting such sublicensee for
Amgen in the definition of Patent Challenger) with respect to any Patent within
the Licensed Technology under which the sublicensee is sublicensed, Amgen will
be permitted to terminate such sublicense agreement.  If a sublicensee of Amgen
(or an Affiliate of such sublicensee) undertakes a Patent Challenge of any such
Patent under which such sublicensee is sublicensed, then Amgen upon receipt of
notice from Micromet of such Patent Challenge, will use commercially reasonable
efforts to terminate the applicable sublicense agreement.  If Amgen fails to so
promptly terminate such sublicense agreement, Micromet may, by written notice to
Amgen, terminate Amgen’s right hereunder to sublicense the Patent(s) at issue to
such sublicensee.
 
8.10       [***] Technology.  To the extent either Party desires to collaborate
with the other Party with respect to [***] Technology as applicable to any
Product, and obtain a license under any such Patents or Know-How of the other
Party, such Party will provide written notice to the other Party, and the
Parties will negotiate in good faith for a reasonable period of time the terms
(including sublicense terms) of such license under the applicable Patents or
Know-How; provided, that in no event will such other Party be obligated to
negotiate such terms for longer than a period of [***] ([***])[***] after
receipt of such notice from the requesting Party.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
37

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

9.           Fees and Payments
 
9.1          Initial Fees.  In consideration of the rights and licenses to Amgen
hereunder, within ten (10) days after the Effective Date, Amgen will pay to
Micromet (a) a non-refundable, non-creditable initial license fee in the amount
of Six Million Euros (€6,000,000), and (b) an advance payment of [***]
Collaboration Expenses in an amount equal to Four Million Euros (€4,000,000)
(the “Advance Payment”), which amount will be credited towards [***]
Collaboration Expenses to be reimbursed by Amgen pursuant to Section 9.2.
 
9.2         Contribution of Parties to [***] Collaboration Expenses.  As
described above, the Development Plan will include a budget of [***]
Collaboration Expenses to be incurred.  Amgen will be responsible for all costs
incurred by Micromet after the Effective Date in the development of the Products
in accordance with the Development Plan and will therefore pay Micromet for
[***] Collaboration Expenses in the manner set forth in this Section 9.2.
 
9.2.1       Amgen will, within the first [***] ([***])[***] of the start of each
Calendar Quarter for which such reimbursement is due, advance to Micromet the
amount of any [***] Collaboration Expenses budgeted for such Calendar
Quarter.  From and after such time as the [***] Collaboration Expenses exceed
the Advance Payment amount, Micromet will report to Amgen within [***]
([***])[***] after the end of each Calendar Quarter with regard to the [***]
Collaboration Expenses actually incurred by it during such Calendar
Quarter.  Such report will specify in reasonable detail (as reasonably requested
by Amgen) all [***] Collaboration Expenses during such Calendar Quarter and will
be accompanied by invoices, or such other appropriate supporting documentation
as may be reasonably required by Amgen.  The Parties will seek to resolve any
questions related to such accounting statements as promptly as possible
following receipt by Amgen of Micromet’s report hereunder. If the amount of
actual [***] Collaboration Expenses incurred during such Calendar Quarter
exceeds the amount of Amgen’s pre-payment, then the terms of Section 9.2.2 will
apply.  If the amount of actual [***] Collaboration Expenses incurred during
such Calendar Quarter is less than the amount of Amgen’s pre-payment, then
Micromet will credit the amount of such overpayment against the subsequent
pre-payment of [***] Collaboration Expenses hereunder.
 
9.2.2       If Micromet anticipates that the aggregate [***] Collaboration
Expenses that are subject to reimbursement under this Section 9.2 for a Calendar
Quarter may exceed an amount equal to [***] percent ([***]%) of the [***] for
the [***] as [***] in the [***] (regardless of the [***] in which the [***] such
[***] to be [***]), as applicable (such excess amount, a “Cost Overrun”), then
Micromet will give notice to the Co-Chairs of the JSC of such anticipated Cost
Overrun, together with an explanation for such Cost Overrun.  Subject to
approval of the JSC, such approval not to be unreasonably withheld, Amgen will
reimburse Micromet for such Cost Overrun, except to the extent such Cost Overrun
for a given Calendar Quarter was caused by Micromet’s [***] to [***] the [***]
using [***].

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
38

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

9.2.3       Upon termination or expiration of this Agreement, or in the event
that Amgen reasonably determines, after consultation with Micromet, that no
further activities under the Development Plan are contemplated to be performed
by Micromet that would result in [***] Collaboration Expenses hereunder,
Micromet will pay to Amgen in immediately available funds any remaining amounts
that have been advanced to Micromet by Amgen pursuant to this Section 9.2 and
which have not otherwise been applied to [***] Collaboration Expenses, within
[***] ([***])[***] after such termination, expiration or determination.
 
9.3          Target Selection; Development and Commercial Milestones.  Amgen
will pay Micromet each of the non-refundable payments in the amounts set forth
on Exhibit F attached hereto within [***] ([***])[***] after the first
occurrence of the corresponding event described on such exhibit on a
Product-by-Product basis; provided, that once a particular milestone has been
paid with respect to any [***] to a particular [***], such milestone will not be
paid if the applicable milestone event is achieved by another [***] to such
[***].
 
9.4          Royalties.
 
9.4.1       Royalty Rates.  Without limitation of Amgen’s rights and obligations
to [***] into [***] for the [***] of [***] pursuant to Section 18.4.3(b), within
[***] ([***])[***] of the end of each Calendar Quarter during the Term during
which there were Net Sales of a Product in the Territory, Amgen will pay (on a
[***] basis and in accordance with Section 10.1) to Micromet a royalty equal to:
 
(a)           [***] percent ([***]%) of the annual, worldwide, aggregate Net
Sales less than or equal to €[***] of such Product;
 
(b)           [***] percent ([***]%) of the annual, worldwide, aggregate Net
Sales greater than €[***] and less than or equal to €[***] of such Product; and
 
(c)           [***] percent ([***]%) of the annual, worldwide, aggregate Net
Sales greater than  €[***] of such Product.
 
By way of example, if, during any calendar year during the Royalty Term, the
amount of Net Sales of a Product is €[***], Micromet will receive [***]% of
€[***] + [***]% of €[***] + [***]% of €[***].
 
9.4.2       Royalty Term. Royalties due under the preceding Section 9.4.1 will
commence upon First Commercial Sale of a Product in a particular country in the
Territory and will expire on a country-by-country basis upon the later of: (i)
the [***] of the [***] of any [***] within the [***] (including any [***] within
the [***]) that [***] by the [***] or [***] of the [***] in such [***] by an
[***], including [***] comprising any [***] or [***], and (ii) [***]
([***])[***] from the First Commercial Sale of such Product in such country
(such period, the “Royalty Term”).

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
39

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

9.4.3      Royalty [***] Upon [***].  The royalty rates set forth in Section
9.4.1 applicable to a particular Product and particular country will [***] by
[***]% at such time as the [***] in [***] of [***] has [***], for the remainder
of the [***] for such Product in such country.
 
9.4.4      [***] Royalty [***].  In no event will any [***] due to Micromet
under this Agreement be [***], in the [***], by more than [***]% pursuant to all
[***] or [***] by Amgen under Sections [***] and [***] of this Agreement.
 
9.5          Payments under Third Party Agreements.
 
9.5.1      Micromet will be responsible for any payments that become due to the
licensors or assignors under (i) any license or right that is obtained by
Micromet with respect to Patents that would be infringed, absent a license, by
the following technologies or activities, or with respect to Know-How that has
been [***] or [***] in connection with the following technologies or activities:
(a) the [***] of a Product, the [***], the [***] in the Products, or the [***]
of an [***] that is a [***], (b) the [***] of [***], as conducted by Micromet at
or prior to the time the [***] are [***] to Section [***], or (c) the [***] of
the [***] as incorporated into a Product, (ii) the [***], or (iii) any
inventorship agreement or arrangement covered by Section 7.9.  For clarity, with
respect to [***], Micromet will be responsible for any payments due under the
[***] itself, but not for payments due under any [***] (which [***] payments
will be Amgen’s responsibility as described in Section 9.5.2
below).  Notwithstanding the foregoing, Micromet will not be responsible for any
payments to Third Parties in connection with licenses to Third Party Patents or
Know-How that Amgen, whether in the relevant Development Plan or otherwise,
[***] to [***] and [***] in connection with the research or development of
Products under this Agreement, or that become necessary solely on account of
[***] or other [***] either to [***] or [***] following the [***] of the [***]
hereunder.
 
9.5.2      Except as described in Section 9.5.1, Amgen will be responsible for
any payments that become due under any agreements under which Amgen or any of
its sublicensees obtains a license or otherwise acquires rights to intellectual
property for the development, manufacture, storage, handling, use,
Commercialization, importation or other Exploitation of Products, including any
[***] obtained from [***] for the use of [***] and [***]; provided, that,
subject to Section 9.4.4, Amgen may [***] from [***] and [***] otherwise [***]
to Micromet hereunder [***]% of any [***] (other than [***] for [***] and [***]
or other [***] or [***]) made to a Third Party for intellectual property that is
[***] for the [***] of Products; and provided, further, that no such [***] will
[***] the [***] payable to Micromet for a [***] by more than [***]%.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
40

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

9.5.3      In the event Micromet is bound to a Third Party for payments
described in Section 9.5.1 for which Amgen is responsible under Section 8.3 or
8.4, then (a) Micromet will make such payment directly to the Third Party in
accordance with the terms of such Third Party agreement, and Amgen will be
obligated to make such payments directly to Micromet in advance of the date such
payments are due to the Third Party or (b) at Amgen’s option, Amgen will make
such payment directly to the Third Party in accordance with the terms of such
Third Party agreement, in which case Micromet will timely provide to Amgen the
payment terms of such Third Party agreement and such Third Party’s payment
information.  Promptly following the Effective Date, the Parties will establish
a mutually acceptable process to facilitate the timely and accurate payment of
such Third Party payments.
 
10.         Payment Terms
10.1       Payment Method; Interest.  All amounts due hereunder to Micromet will
be paid in Euros by wire transfer in immediately available funds to an account
designated by Micromet.  Any payments or portions thereof due hereunder which
are not paid on the date such payments are due under this Agreement will bear
interest at the lower of (i) [***] ([***])[***] over the overnight LIBOR rate in
effect on the due date, or (ii) the maximum rate permitted by law, calculated on
the number of days such payment is delinquent, compounded monthly.
 
10.2        Tax Matters.
 
10.2.1    Taxes.  All excises, taxes, and duties, with the exception of value
added taxes (“VAT”) (collectively “Taxes”) levied on account of a payment made
by Amgen to Micromet pursuant to this Agreement will be the responsibility of
and paid by Micromet or will be subject to the withholding, remittance, and
offset provisions of this Section 10.2 as provided herein.
 
10.2.2    Withholding by Amgen.  In the event that laws or regulations require
Amgen to pay or withhold Taxes with respect to any payment to be made by Amgen
pursuant to this Agreement, Amgen will withhold such Taxes from the amount due
and furnish Micromet with proof of payment of such Taxes.  Amgen will provide
reasonable assistance to Micromet in its efforts to claim an exemption of Taxes,
obtain a refund of Taxes withheld, or obtain a credit with respect to such Taxes
paid.  In order for Micromet to secure an exemption from, or a reduction in, any
withholding of Taxes, Micromet will provide to Amgen a completed Form W-8
applicable to each type of payment to be made pursuant to this Agreement for
which an exemption from, or a reduction in, any withholding of Taxes is
claimed.  Micromet will provide such completed form(s) within ten (10) days of
the Effective Date of this Agreement (or prior to payment of any amount due
under this Agreement, if such payment is due sooner than ten (10) days after the
Effective Date).  In the event that a form previously furnished to Amgen
expires, is incorrect, or does not apply to the type of payment to be made, due
to a change in circumstances or otherwise, Micromet will furnish a new form to
Amgen prior to the payment of any such amount in order to secure an exemption
from, or a reduction in, any withholding of Taxes with respect to such payment.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
41

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

10.2.3    Withholding Taxes Resulting From Amgen Action.  If Amgen (or any of
Amgen’s Affiliates or successors) is required to make a payment to Micromet
subject to a deduction or withholding of Taxes and such deduction or withholding
obligation arises as a result of any change in circumstance undertaken by Amgen
or Amgen’s Affiliates or successors after the Effective Date—including a change
of domicile, any assignment or transfer of all or a portion of this Agreement as
permitted under this Agreement or any sublicense of rights or obligations
hereunder to an Affiliate or Third Party—or such change in circumstance has the
effect of increasing the amount of Taxes deducted or withheld (an “Amgen
Withholding Tax Action”), then notwithstanding Section 10.2.1, (a) the payment
by Amgen (in respect of which such deduction or withholding of Taxes is required
to be made) will be increased by the amount necessary (the “Additional Amounts”)
to ensure that Micromet receives an amount equal to the same amount that it
would have received had no Amgen Withholding Tax Action occurred, and (b) the
Additional Amounts will be deducted and withheld by Amgen from the increased
payment made by Amgen to Micromet.  If Micromet receives a refund or claims a
tax credit with respect to any withholding taxes for which Amgen has made a
payment to or on behalf of Micromet pursuant to this Section 10.2.3, then
Micromet shall pay to Amgen an amount equal to such refund or equal to the
actual reduction of Micromet’s otherwise payable taxes that results from such
credit (but only to the extent of additional amounts received by Micromet
pursuant to this Section with respect to the taxes giving rise to such refund or
credit) without interest; provided, however, that the determination of amounts
payable by Micromet shall be reasonably determined by Micromet and may take into
account all other tax attributes and items of Micromet prior to giving effect to
any credit for withholding taxes with respect to payments hereunder.  Payments,
if any, under the preceding sentence: (i) will not be required after the [***]
following the last tax year in which Micromet receives a payment under this
Agreement, and (ii) will be paid by Micromet promptly following the receipt of a
refund or following the filing of the tax return on which a credit is
claimed.  If, with respect to the payments contemplated by this Section 10.2.3,
any taxing authority disallows all or a portion of Micromet’s claimed credit or
requires a return of all or any portion of a refund received by Micromet (an
“Adjustment”), then Amgen shall pay Micromet or its Affiliates an amount equal
to the Adjustment.
 
10.2.4    Amgen’s Right of Offset.  In the event that a tax authority
retroactively determines that a payment made by Amgen to Micromet pursuant to
this Agreement should have been subject to withholding (or to additional
withholding) for Taxes, and Amgen remits such withholding tax to the tax
authority, Amgen will have the right to offset such amount (including any
interest and penalties that may be imposed thereon) against future payment
obligations of Amgen under this Agreement; provided, however, that if no further
payments or insufficient further payments are available against which offset may
be pursued, Amgen may pursue reimbursement by any remedy (at law or in equity)
available to it.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
42

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

10.2.5    VAT.  All payments due Micromet from Amgen pursuant to this Agreement
will be paid exclusive of any VAT (which, if applicable, will be payable by
Amgen upon receipt of a valid VAT invoice).
 
10.3       Reports.  With respect to each Calendar Quarter for which royalties
are due hereunder, within [***] following the date on which Amgen publicly
discloses such information in its quarterly earnings report for such Calendar
Quarter (but no later than [***] ([***])[***] following the end of such Calendar
Quarter), Amgen will provide Micromet with a good faith estimate of Net Sales of
each Product in the Territory during such Calendar Quarter.  Amgen will
accompany each payment of royalties under this Agreement with a report
containing a detailed and itemized calculation of Net Sales of a Product in the
Territory during the preceding Calendar Quarter, including a description of the
dates and territories in which Product sales were made, in a manner that is
consistent with the method generally used by the Amgen Finance Department to
track such information for Amgen’s other commercialized products in the
Territory.
 
10.4       Currency Conversion. For any currency conversion required in
determining the amount of royalties due, the amount of Net Sales in any non-Euro
currency will be computed by converting such amount into Euros.  Such conversion
will be made in a manner consistent with the provisions of U.S. GAAP and Amgen’s
normal practices used to prepare its audited financial statements for internal
and external reporting purposes, which uses a widely accepted source of
published exchange rates.  Except as provided in Section 10.2, all payments due
under this Agreement will be paid in full without deduction for any withholding
or value added tax.
 
10.5       Records Retention; Audit.
 
10.5.1    Record Retention.  Each Party will maintain complete and accurate
books, records and accounts used for the determination of (a) any [***]
Collaboration Expenses that Amgen is required to reimburse under this Agreement
and (b) Net Sales, in sufficient detail to confirm the accuracy of any payments
required under this Agreement, which books, records and accounts will be
retained by such Party until [***] ([***])[***] following the end of the
calendar year to which such books, records and accounts pertain.
 
10.5.2    Audit.  Each Party will have the right to have an independent
certified public accounting firm of internationally recognized standing,
reasonably acceptable to the other Party, have access during normal business
hours, and upon reasonable prior written notice, to such of the records of the
other Party and its Affiliates as may be reasonably necessary to verify the
accuracy of Micromet Collaboration Expenses or Net Sales for any one or more
Calendar Quarters ending not more than [***] ([***])[***] prior to the date of
such request; provided, however, that no Party will have the right to conduct
more than [***] such audit in any [***].  The accounting firm will disclose to
the Parties only whether the Micromet Collaboration Expenses or Net Sales
reported by the audited Party are correct or incorrect and the specific details
concerning any discrepancies.  The auditing Party will bear all costs of such
audit, unless the audit reveals a discrepancy in the auditing Party’s favor of
more than [***] percent ([***]%) of the amount paid for a period covered by the
audit, in which case the audited Party will bear the cost of the audit.  The
results of such accounting firm will be final, absent manifest error.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
43

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

10.5.3    Payment of Additional Amounts.  If, based on the results of any audit,
additional payments are owed to a Party under this Agreement, then the other
Party will make such additional payments promptly after the accounting firm’s
written report is delivered to both Parties.  If, based on the results of any
audit, any payments made by a Party to the other Party exceeded the amounts due
and payable under this Agreement, then the receiving Party will return such
excess to the other Party promptly after the accounting firm’s written report is
delivered to both Parties.
 
10.5.4    Confidentiality.  Each Party will treat all information subject to
review under this Section 10.5 in accordance with the provisions of Article 11
and will cause its accounting firm to enter into a reasonably acceptable
confidentiality agreement with the audited Party obligating such firm to
maintain all such financial information in confidence pursuant to such
confidentiality agreement.
 
11.         Confidentiality
 
11.1       Definition.  During the Term and subject to the terms and conditions
of this Agreement, a Party (the “Disclosing Party”) may communicate to the other
Party (the “Receiving Party”) information in connection with this Agreement or
the performance of its obligations under this Agreement, including any
information in reports provided pursuant to this Agreement, scientific and
manufacturing information and plans, marketing and business plans, and financial
and personnel matters relating to a Party or its present or future products,
sales, suppliers, customers, employees, investors or business (collectively,
“Confidential Information”).  The Parties agree that the terms of this Agreement
are deemed Confidential Information of both Parties and will be subject to the
restrictions on use and disclosure set forth herein.  Confidential Information
also includes any information disclosed prior to the Effective Date pursuant to
that certain Confidential Disclosure Agreement between the Parties dated [***].
 
11.2        Exclusions.  Notwithstanding the foregoing, any information of a
Party will not be deemed Confidential Information with respect to the Receiving
Party for purposes of this Agreement if such information:
 
11.2.1    was already in the possession of the Receiving Party or its Affiliates
at the time of disclosure to the Receiving Party, as evidenced by the Receiving
Party’s written records, other than under an obligation of confidentiality or
non-use to the Disclosing Party;
 
11.2.2    was generally available in or was otherwise part of the public domain
at the time of its disclosure to the Receiving Party;

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
44

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

11.2.3    became generally available in the public domain after its disclosure
to the Receiving Party, other than through the Receiving Party’s breach of its
obligations under this Article 11;
 
11.2.4    was disclosed to the Receiving Party, other than under an obligation
of confidentiality or non-use, by a Third Party who had no obligation to the
Disclosing Party not to disclose such information to others; or
 
11.2.5    was independently discovered or developed by the Receiving Party or
its Affiliates, as evidenced by their written records, without the use of or
reference to any Confidential Information of the Disclosing Party.
 
11.3       Disclosure and Use Restriction.  Except as expressly provided herein,
the Parties agree that, during the Term and for [***] ([***])[***] thereafter,
each Party and its Affiliates will keep completely confidential and will not
publish or otherwise disclose any Confidential Information of the other Party or
its Affiliates.  Neither Party will use any Confidential Information of the
other Party without such other Party’s consent, except as contemplated by this
Agreement (including, by way of example, by incorporating such Confidential
Information into a Patent filing in contravention of this Agreement).  Upon any
termination of this Agreement, a Receiving Party will, at its own cost and
expense, promptly return to the Disclosing Party all Confidential Information of
the Disclosing Party and destroy where practicable all copies of the foregoing
or any portion thereof (other than a single archival copy retained solely for
record keeping purposes).
 
11.4        Authorized Disclosure.  Each Party or its Affiliates may use and
disclose Confidential Information of the other Party to the extent that such use
and disclosure is:
 
11.4.1    made in response to a valid order of a court of competent jurisdiction
or other governmental or regulatory body of competent jurisdiction or as
required by applicable laws or regulations or under the rules of any nationally
recognized security exchange; provided, that such Party will first have given
notice to such other Party and given such other Party a reasonable opportunity
to quash such order and to obtain a protective order or confidential treatment
requiring that the Confidential Information and documents that are the subject
of such order be held in confidence by such court or governmental or regulatory
body or, if disclosed, be used only for the purposes for which the order was
issued; provided, further, that if a disclosure order is not quashed or a
protective order is not obtained, the Confidential Information disclosed in
response to such court or governmental order will be limited to that information
which is legally required to be disclosed in response to such court or
governmental order; and provided, further, that with respect to complying with
the disclosure requirements of the SEC in connection with any required SEC
filing of this Agreement, the Parties will consult with one another concerning
which terms of this Agreement will be requested to be redacted in any public
disclosure of this Agreement by the SEC;

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
45

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

11.4.2    made by such Party to the Regulatory Authorities as required in
connection with any filing of INDs, BLAs, Marketing Approval applications, or
similar applications or requests for regulatory approvals with respect to a
Product; provided, that reasonable measures will be taken to request
confidential treatment of such information;
 
11.4.3    made by such Party, in connection with the performance of this
Agreement (including the exercise of rights granted hereunder), on a
need-to-know basis to Affiliates, sublicensees, research parties, employees,
consultants, representatives or agents, each of whom prior to disclosure must be
bound by obligations of confidentiality and non-use at least equivalent in scope
to those set forth in this Article 11;
 
11.4.4    made by such Party to its existing or potential acquirers or merger
candidates, investment bankers or existing or potential investors, including
venture capital firms or other financial institutions, each of whom prior to
disclosure must be bound by obligations of confidentiality and non-use at least
equivalent in scope to those set forth in this Article 11; provided, that such
disclosure will be limited to the existence of this Agreement and its terms;
 
11.4.5    made by such Party in a patent application expressly permitted to be
filed under Section 7, subject to the other Party’s prior consent (which will
not be unreasonably withheld, conditioned or delayed); provided, that reasonable
measures will be taken to request confidential treatment of such information, to
the extent such protection is available; or
 
11.4.6    made in prosecuting or defending litigation pertaining to this
Agreement; provided, that reasonable measures will be taken to request
confidential treatment of such information and to limit the information
disclosed to that which is reasonably necessary for such prosecution or defense.
 
12.           Public Communications
 
12.1       General Provisions.  The Parties will cooperate with respect to the
timing and content of communications with the public regarding the development
and marketing of a Product, in accordance with the provisions of this Section
12.
 
12.2       Press Releases.
 
12.2.1    The Parties agree that the public announcement of the execution of
this Agreement will be made by a press release issued by Micromet, which such
press release will be substantially in the form of the press release attached as
Exhibit G.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
46

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

12.2.2    With respect to any other proposed press release by Micromet relating
to this Agreement or to the performance hereunder, Micromet will provide a draft
of the release to Amgen at least [***] ([***])[***] prior to the proposed
disclosure for review, comment and consent by Amgen, and Amgen will provide such
comments and consent within such [***] ([***])[***] period (with any failure to
so respond being deemed consent thereto), except that the following disclosures
may be made without the prior consent of Amgen: (i) any disclosure which is
required by applicable law, including disclosures required by the SEC or made
pursuant to the rules of the national securities exchange or other stock market
on which Micromet’s securities are traded, as advised by Micromet’s counsel, and
(ii) disclosure of the receipt by Micromet of any milestone payments (including
the amounts thereof, only if required, in the reasonable opinion of Micromet’s
counsel, to be disclosed pursuant to applicable U.S. securities laws and
regulations, including any such requirement to be disclosed in Micromet’s next
periodic report); provided, that in each case (a) Micromet will give Amgen
prompt notice (not less than [***] ([***])[***] prior to disclosure) and (b) to
the extent practicable will provide Amgen an opportunity to comment on the
proposed disclosure.
 
12.2.3    Until the completion of the [***], Amgen will submit to Micromet for
its review and comment any other press releases by Amgen relating to this
Agreement or to the performance hereunder; provided, for clarity, that release
of such disclosure will be at Amgen’s sole and absolute discretion.
 
12.3        Publications and Presentations.
 
12.3.1    Micromet will not, without Amgen’s prior written consent, publish,
whether in print or electronic media or in presentation at conferences or
otherwise, any publication that contains clinical data, or pertains to results
of clinical studies or other studies, with respect to a Product, or otherwise
pertains to activities performed pursuant to the [***] or under the Development
Plan.
 
12.3.2    At least [***] ([***])[***] prior to submission of any publication not
covered by Section 12.3.1 that contains clinical data, or pertains to results of
clinical studies or other studies conducted under this Agreement or otherwise
pertains to activities performed under this Agreement, or includes Confidential
Information of the other Party, for publication in print or electronic media or
presentation at conferences, the submitting Party will provide to the other
Party a draft of such material for its review and comment.  The receiving Party
will provide any comments to the submitting Party within [***] ([***])[***] of
receipt of such materials, and the submitting Party will review and consider in
good faith any comments provided by the other Party.  In addition, any
information determined by the other Party to be its Confidential Information
must be removed upon request of the other Party.  If requested in writing by the
other Party, the submitting Party will withhold material from submission for
publication or presentation for an additional [***] ([***])[***] to allow for
the filing of a patent application or the taking of such measures to establish
and preserve proprietary rights in the information in the material being
submitted for publication or presentation.
 
12.4        Previous Disclosures.  A Party may publicly disclose without regard
to the requirements of this Section 12 any information that was previously
disclosed in compliance with such requirements.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
47

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

13.           Term and Termination
 
13.1       Term.  This Agreement will commence on the Effective Date and will
continue in full force and effect until the expiration of the last-to-expire
Royalty Term for any Product then being developed or Commercialized (such
period, the “Term”), unless earlier terminated as provided in this Agreement.
 
13.2       Termination at Will.  Amgen may terminate this Agreement in its
entirety, or on a worldwide basis with respect to a particular Feasibility
Target or Collaboration Target, at any time upon [***] ([***]) [***] prior
written notice to Micromet.  In addition, Amgen may terminate this Agreement
solely with respect to a [***] in a [***] at any time following the [***] of a
[***] in a [***], upon [***] ([***])[***] prior written notice to Micromet.
 
13.3        Termination for Material Breach.
 
13.3.1    If a Party (the “Breaching Party”) commits a material breach of this
Agreement, the other Party (the “Non-Breaching Party”) may give to the Breaching
Party written notice specifying the nature of the material breach and requiring
the Breaching Party to make good or otherwise cure such material breach.
 
13.3.2    If such material breach is not cured within [***] ([***])[***] after
the receipt of notice pursuant to Section 13.2.1 above (or within [***]
([***])[***] notice in the event such breach is solely based upon the breaching
Party’s failure to pay any amounts due hereunder), the Non-Breaching Party will
have the right, on written notice to the Breaching Party, to terminate this
Agreement without prejudice to any of its other rights and remedies conferred on
it by this Agreement or by law; provided, that if the Breaching Party disputes
in good faith the grounds of such termination, then (a) the [***] of such [***]
and the [***] of [***] under Section [***] will be [***] the [***] of the [***]
described in Section 18.4; (b) each Party will continue to perform its
obligations under this Agreement and (c) following the resolution of such
dispute pursuant to Section 18.4, in lieu of any [***] or prior to [***]
exercise of its rights under Section [***] (in the event of a material breach by
[***]), the Breaching Party will [***] the [***] to [***] (i) any [***] breach
by [***] of any [***] and (ii) any other breach that the Breaching Party [***]
can be [***] by the [***] of [***] or [***].
 
14.           Effects of Termination
 
14.1       Program Transfer upon Termination.  Upon any termination of this
Agreement pursuant to Section 13.2, or pursuant to Section 13.3 by reason of a
material breach by Amgen, Amgen will transition to Micromet the research,
development and Commercialization of Research Candidates and Products in the
Territory, to the extent set forth below in this Section 14.1 (such transfer as
listed below hereafter referred to as the “Program Transfer”).  In such regard,
Amgen hereby agrees to (effective only in event of such termination) and will,
to the extent applicable and to the extent requested by Micromet:

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
48

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

(a)           transfer and assign to Micromet all Regulatory Filings and
Marketing Approvals for such Products in the Territory, as permitted under
applicable law, and provide to Micromet copies of all data (including all
clinical trial data irrespective of whether such trial is being continued,
except as provided in Section 14.4 with respect to [***]), materials, reports,
information and other Know-How (to the extent such Know-How is not generally
known and has been incorporated into a Product) relating to such Products,
Regulatory Filings and Marketing Approvals, or that are otherwise [***] for
Micromet to continue the development of such Products, all to the extent the
foregoing are in Amgen’s possession or control as of the effective date of such
termination (the “Termination Effective Date”) and have not previously been
provided to Micromet hereunder, and all of which shall be deemed both Amgen’s
Confidential Information and Micromet’s Confidential Information; provided, that
such confidentiality obligations will not be construed to limit Micromet’s
ability to Exploit the applicable Research Candidates and Products following the
Program Transfer as contemplated in this Article 14, including disclosures to
Third Parties in connection with such Exploitation.  To the extent any such
Regulatory Filings or Marketing Approvals are not assignable, Amgen will make
available to Micromet the benefits of such Regulatory Filings and Marketing
Approvals until they may be so assigned; provided, that Micromet uses all
reasonable efforts to assist in effecting such assignment or otherwise making
such assignment unnecessary;
 
(b)           in the event there are any clinical trials of any Product in the
Territory that are anticipated to be conducted by Amgen as of the Termination
Effective Date, then Amgen will provide prompt written notice thereof to
Micromet (which notice shall be provided no more than [***] ([***])[***] from
the date of a termination notice delivered by Amgen).  Within [***] ([***])[***]
of receipt of such notice, Micromet will inform Amgen whether Micromet desires
Amgen to [***] any or all of such [***] to [***] (any such [***], a
“[***]”).  Amgen will cooperate to promptly transition to Micromet (or its
designee) the sponsorship and management of [***] and [***] to support such
[***] for such Product in the Territory;
 
(c)           transfer to Micromet (or its designee) all clinical and commercial
supplies of Products in Amgen’s possession or control as of the Termination
Effective Date, and return to Micromet any remaining quantities of Research
Candidates that Micromet provided to Amgen in connection with the Development
Plan;

 
(d)           if Amgen is manufacturing Product when notice of termination is
provided, complete all manufacturing batches of Products that are in process as
of the Termination Effective Date, and transfer such quantities of Products to
Micromet in accordance with subsection (c) above upon completion; and upon
Micromet’s request, supply Micromet with such Product for clinical development
or commercial sale in the Territory in accordance with reasonable forecasting
and ordering procedures to be agreed, in the quantity that is the greater of:
(i) the [***] from a [***] Product [***] conducted at the [***] (or, at a [***]
if the then-current [***] exceeds the [***]) and (ii) the amount of Product drug
substance [***] to [***] Micromet to [***] of Product [***] as of the
Termination Effective Date; provided, that Micromet will use commercially
reasonable efforts to obtain an alternative source for such Products for
clinical development or commercial sale in the Territory as soon as
practicable.  Notwithstanding the foregoing, Amgen will only be required to
supply to Micromet those Products for which Amgen has established a
manufacturing process for GMP-grade materials as of the Termination Effective
Date, either itself or through a Third Party contract manufacturer;

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
49

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

(e)           provide to Micromet (or, at either Party’s option, to a Third
Party contract manufacturer that is located in the United States, the EU, Canada
or Japan and is mutually agreed by the Parties) a copy of all [***] and other
[***] to manufacture Products for clinical development or commercial sale in the
Territory, including any [***] such as [***], and to the extent not previously
provided to Micromet hereunder; provided, that Amgen may only withhold its
consent to a Third Party contract manufacturer selected by Micromet on the basis
of [***] concerns relating to such Third Party’s practices regarding the [***]
or other [***]; and provided, further, that Amgen will [***] to [***] Micromet
with a [***] of [***] ([***]), but at least [***] ([***]) Third Party [***] that
would be [***] to [***] and that are [***], and [***] under Applicable Law, of
[***] of Product in the [***] and [***] required to [***] or [***] of the
Product (it being understood that by [***], Amgen is not making any
representation or warranty with respect to such [***] or [***], and shall not be
[***] to any [***] arising from the [***] or [***] of any such [***]);
 
(f)           at Micromet’s request prior to the Termination Effective Date,
assign to Micromet any or all agreements between Amgen and Third Parties
relating solely to the development or manufacture of such Product in the
Territory, to the extent permissible under the terms of such agreements.  To the
extent any such agreements are not assignable, Amgen will make available to
Micromet the benefits of such agreements (including, in the case of
manufacturing agreements, by [***] Product from the [***] in accordance with the
terms of such agreement for shipment to Micromet) to the extent necessary for
the continued development or manufacture until they may be so assigned;
provided, that Micromet uses all reasonable efforts to assist in effecting such
assignment or otherwise making such assignment unnecessary;
 
(g)           assign to Micromet its entire right, title and interest in and to
any Product-specific trademarks, trade dress, logos, slogans, designs and
copyrights, in each case, used for the Products in the Territory as of the
Termination Effective Date, including any registrations for the foregoing (but
excluding any Amgen company marks or marks used with any other Amgen products);
 
(h)           subject to Section 14.3.1 below, grant to Micromet a
royalty-bearing, non-exclusive license (with the right to grant and authorize
the further grant of sublicenses through multiple tiers) under any [***]
Technology (which, for purposes of this Section 14.1(h), will include [***]
Technology, [***] Technology, [***] Technology (solely to the extent required to
comply with the [***] of a [***] or other [***]) and [***] that, but for the
[***] in the definition of [***] Technology, meets the criteria of [***]
Technology) and that is (i) [***] for the [***] of the Research Candidate(s) and
Product(s) and (ii) [***] (or [***] to [***]) by Amgen in the [***] of the [***]
and [***] in the Territory as of the Termination Effective Date, and Amgen’s
interest in any [***] Technology, in each case, to Exploit the Research
Candidate(s) and Product(s) in the Territory; provided, that the foregoing
license will be exclusive with respect to Exploitation of any Product(s) for
which Amgen [***] prior to the Termination Effective Date (each, a “Reverted
Product”);

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
50

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

(i)           for Research Candidates, and Products that are not Reverted
Products: upon request of Micromet prior to the Termination Effective Date,
subject to Section 14.3.2 below, grant to Micromet a royalty-bearing license
(with the right to grant and authorize the further grant of sublicenses) under
any [***] Technology (which, for purposes of this Section 14.1(i), will include
[***] and, if available, [***] that, but for the [***] in the definition of
[***] Technology, meet the criteria of [***] Technology) that (i) is [***] for
the use of [***] and [***] incorporated into the Research Candidate(s) and
Product(s) and (ii) was [***] (or [***] to [***]) by Amgen in the [***] of the
[***] and [***] (other than [***]) in the Territory as of the Termination
Effective Date, to [***] such [***] and [***] in the Territory.  The license
under this Section 14.1(i) will be exclusive or non-exclusive as so requested by
Micromet; provided, that, to the extent Amgen Controls any such [***] Technology
on a non-exclusive basis or such Control is subject to other limitations, the
foregoing grant will be no greater than the extent of such Control; and
 
(j)           for Reverted Products:  upon request of Micromet prior to the
Termination Effective Date, subject to Section 14.3.2 below, grant to Micromet a
royalty-bearing license (with the right to grant and authorize the further grant
of sublicenses) under any [***] Technology (which, for purposes of this Section
14.1(j), will include [***] Technology (solely to the extent required to comply
with the [***] of a [***] or other [***]),[***] Technology, [***] Technology and
[***] that, but for the [***] in the definition of [***] Technology, meets the
criteria of [***] Technology) that (i) is [***] for the [***] of [***] and
(ii) was [***] (or [***] to [***]) by Amgen in the [***] of such [***] in the
Territory as of the Termination Effective Date, to [***] the [***] in the
Territory.  The license under this Section 14.1(j) will be exclusive or
non-exclusive as so requested by Micromet; provided, that, to the extent Amgen
Controls any such [***] Technology on a non-exclusive basis or such Control is
subject to other limitations, the foregoing grant will be no greater than the
extent of such Control).
 
14.2       [***] Termination.
 
14.2.1    Termination With Respect to [***].  Upon termination of this Agreement
by Amgen on a worldwide basis with respect to a [***] or [***] pursuant to
Section 13.2, the [***] or [***] specified in Amgen’s notice of termination (the
“[***]”) will cease to be a [***] or [***], as applicable, for all purposes of
this Agreement.  In such event, Section 14.1 above will apply only with respect
to [***],[***] and [***] binding to the [***] (each a “Terminated Product”) in
the Territory, mutatis mutandis, such that each reference in Section 14.1 to
“Product” will be deemed a reference to “Terminated Product;” provided (i) to
the extent that Amgen may use for other Products any of the trademarks or other
items described in Section 14.1(g) above, then Section 14.1(g) will not apply
and Amgen will instead grant to Micromet a license to Exploit such trademarks
and other items for purposes of the Terminated Products in the Territory; and
(ii) for clarity, Section 14.1(h) (solely with respect to the proviso in such
subsection) and Section 14.1(j) above will apply only to the extent a Terminated
Product is a Reverted Product.  The terms and conditions of this Agreement will
continue in full force and effect with respect to any [***] or [***] other than
such [***], and the terms and conditions of the provisions listed as surviving
pursuant to Section 14.9 will continue in full force and effect with respect to
the [***].

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
51

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

14.2.2    Termination With Respect to [***].  Upon any termination of this
Agreement with respect to a [***] in a [***] pursuant to Section 13.2, the [***]
specified in Amgen’s notice of termination (the “[***]”) will cease to be a
[***] in the [***] specified in such notice (the “[***]”), for all purposes of
this Agreement.  In such case, Section 14.1 above will apply only with respect
to the [***] binding to the [***] (each a “[***]”) in such [***], mutatis
mutandis, such that each reference in Section 14.1 to “[***]” or “[***]” will be
deemed a reference to “[***]” and “[***],” respectively; provided, that (i)
Section 14.1(g) will not apply and Amgen will instead grant to Micromet a
license to Exploit such trademarks and other items [***] for purposes of the
[***]; (ii) Amgen will not be obligated to return Research Candidates pursuant
to Section 14.1(c) and references to “Research Candidate(s) and” in Section
14.1(h) will not apply; (iii) for clarity, Section 14.1(h) (solely with respect
to the proviso in such subsection) and Section 14.1(j) above will apply only to
the extent the Terminated Product is a Reverted Product; and (iv) the license
grant in Section 14.6.3 will [***] but will apply [***] in the [***].  If this
Agreement is terminated with respect to all [***] in a [***], the [***] will
thereafter be deemed to mean all [***] other than the [***], for all purposes of
this Agreement.  The terms and conditions of this Agreement will continue in
full force and effect with respect to any [***] other than such [***] in such
[***], and the terms and conditions of the provisions listed as surviving
pursuant to Section 14.9 will continue in full force and effect with respect to
the [***]; and, in addition, Amgen will continue to have and is hereby granted a
non-exclusive license under the [***] Technology to manufacture, use and develop
Products in the [***], solely for purposes of [***] Products [***] the [***]
(including the right to sublicense in accordance with Section 8.5).
 
14.3        Post-Termination Payments.
 
14.3.1    For [***] Technology and [***] Technology.  In consideration for the
rights granted under Section 14.1 to the [***] Technology and [***] the [***]
Technology, Micromet will pay to Amgen a royalty on net sales by Micromet, its
Affiliates and licensees of Products in the [***].  The royalty rate will be
[***] the [***] that [***] pursuant to [***], as follows: (a) [***] of the [***]
in [***] if the termination occurs after [***] of the [***] for a Product; (b)
[***] of the [***] in [***] if the termination occurs after [***] of the [***]
for a Product and (c) [***] of the [***] in [***] if the termination occurs
after [***] for a Product.  For clarity, if such a termination occurs prior to
the [***] of the [***] for a Product, then the rights granted by Amgen under the
[***] Technology and [***] the [***] Technology under Section 14.1(h) will be
fully-paid and royalty-free.  As used herein, “[***]” of a [***] will mean the
[***] of the [***].  For purposes of the foregoing, “net sales” will be defined
in a manner substantially similar to Net Sales under Section 1.77, and Sections
9.4.2, 9.4.3, 9.5.2 and Article 10 will apply mutatis mutandis.  Notwithstanding
the foregoing, Micromet will make any payments under any license between Amgen
and a Third Party with respect to the [***] Technology and [***] the [***]
Technology described above and any other payments due to Third Parties for any
such intellectual property rights licensed to Amgen resulting from the grant to
Micromet of such license or Micromet’s practice of such license rights.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
52

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

14.3.2    For [***] Technology.  Promptly following the delivery of the
applicable termination notice by a Party under this Agreement and a request by
Micromet in accordance with Section 14.1(i) or 14.1(j), the Parties will [***]
the [***] and [***] for the foregoing license to [***] Technology, taking into
consideration (a) for [***] Technology [***] by Amgen, [***] for [***] in the
[***] of such [***] Technology, (b) for [***] Technology [***] by Amgen, [***]
for such [***] Technology and [***] by Amgen to its [***] resulting from the
[***] of a [***] to Micromet for the development or Commercialization of the
Product and Micromet’s activities thereunder, and (c) for [***] Technology [***]
by Amgen, a [***] of such [***] based on the [***] of such technology for [***],
among other commercially relevant factors.  If the Parties [***] on the [***] of
the [***] license to such license to the [***] Technology within [***] of the
[***] of such [***], then the [***] described in [***] will apply, and Amgen
covenants [***] the [***] of [***] not to [***] Micromet, its Affiliates or any
Third Party sublicensee under any such [***] Technology to [***] Products [***]
to the [***] in the [***].  Notwithstanding the foregoing, Micromet will make
any payments under any license between Amgen and a Third Party with respect to
the [***] Technology described in clause (a) or (b) above and any other payments
due to Third Parties for any such intellectual property rights licensed to Amgen
resulting from the grant to Micromet of such license or Micromet’s practice of
such license rights.
 
14.4        Funding for Program Transfer; [***] Expenses.
 
14.4.1    During the applicable notice period for termination until the
Termination Effective Date, each Party will continue to perform its obligations
in accordance with the terms of this Agreement with respect to Products [***] in
the [***].  During such period, Amgen will not terminate or discontinue any
[***] except with the consent of Micromet or, after consultation with Micromet,
as required by Applicable Law or reasons of [***].  [***] will bear any costs
associated with the conduct of [***] prior to the Termination Effective Date (it
being understood that [***] will reimburse [***], on a pro rata basis, for any
non-cancellable costs incurred by [***] that cover periods following the
Termination Effective Date).  Amgen will have the right to complete or wind down
and terminate any [***] (each, a “[***]”), with such expenses and costs to be
borne by [***] (“[***] Expenses”).  The data, results and associated
intellectual property resulting from any [***] shall be excluded from the rights
conveyed to Micromet under Section 14.1 or elsewhere in this Agreement.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
53

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

14.4.2    Micromet will reimburse Amgen at [***] (after the [***], which will be
[***]) and for all Out-of-Pocket Costs for its implementation of the Program
Transfer, including any payments associated with the transfer of any [***] from
and after the Termination Effective Date, the supply of Product pursuant to
Sections 14.1(d) or (f), as applicable, or the transfer of rights from any Third
Party licensors or assignors, but excluding any [***], such reimbursement to
occur after substantial completion of delivery of the items to be delivered by
Amgen under Section 14.1, [***] such that (a) the first [***] will be [***]
within [***] after such substantial completion or the [***] of the [***]
immediately following such completion, whichever is later, and (b) the [***]
will be [***] on the first day of [***] of the [***].
 
14.5        Termination of Licenses.
 
14.5.1    Certain Terminations.  Upon a termination of this Agreement in its
entirety under Section 13.2 or 13.3 (but not an expiration of this Agreement
under Section 13.1, or a termination [***] under Section 13.2) all rights and
licenses granted by Micromet to Amgen hereunder will terminate.
 
14.5.2    Rights in Bankruptcy. All rights and licenses granted under or
pursuant to this Agreement by Micromet or Amgen are, and will otherwise be
deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code and
other similar laws in a jurisdiction outside the United States, licenses of
rights to “intellectual property” as defined under Section 101 of the U.S.
Bankruptcy Code.  The Parties agree that the Parties, as licensees of such
rights under this Agreement, will retain and may fully exercise all of their
rights and elections under the U.S. Bankruptcy Code or such similar laws in a
jurisdiction outside the United States.  The Parties further agree that, in the
event of the commencement of a bankruptcy proceeding by or against either Party
under the U.S. Bankruptcy Code, the Party hereto that is not party to such
proceeding will be entitled to a complete duplicate of (or complete access to,
as appropriate) any such intellectual property and all embodiments of such
intellectual property, which, if not already in its possession, will be promptly
delivered to them (a) upon any such commencement of a bankruptcy proceeding upon
written request therefor, unless the Party subject to such proceeding elects to
continue to perform all of its obligations under this Agreement, or (b) if not
delivered under clause (a) above, following the rejection of this Agreement by
or on behalf of the Party subject to such proceeding upon written request
therefor by the non-subject Party.
 
14.6       Consequences of Micromet Material Breach.
 
14.6.1    Subject to Section 14.6.2 below, upon any termination of this
Agreement pursuant to Section 13.3 by reason of Micromet’s material breach, at
Micromet’s request, the Parties will [***] for a [***] the [***] of and [***] to
any [***] to [***] of the research, development and Commercialization of
Research Candidates and Products in the Territory (provided, that in no event
will [***] be [***] to [***] for [***] a [***] of [***] the [***] of such [***])
and Amgen will have all rights at law or in equity to pursue any remedies
available under applicable law with respect to such material breach.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
54

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

14.6.2    Without limiting any rights and remedies available under applicable
law, if Amgen has the right to terminate this Agreement under Section 13.3 on
account of Micromet’s material breach, following the exhaustion of the dispute
resolution procedures described in such Section 13.3, then, in lieu of
exercising its rights to terminate this Agreement in its entirety under Section
13.3, Amgen may elect to retain the licenses and rights granted under this
Agreement, in which event Section 14.6.1 above will not apply and this Agreement
will continue in full force and effect; provided, however, the following
provisions will terminate and be of no further force or effect:  (a) Sections
[***] and Article [***] (other than Section [***] and Section [***]) (provided,
that, in connection with the court proceedings pursuant to Section 13.3.2, the
Parties will [***] that [***] the [***] of a given [***] to be more [***] or
[***], or [***] to such [***], and if the [***] that [***] the [***] of such
[***] to be [***] or [***], or [***] in [***] to such [***]  (or does not [***]
with respect to [***]), then Section [***] will [***]; and (b) Amgen’s
obligations and Micromet’s rights under Sections [***] and [***] will
terminate.  In addition, Article 2 will terminate, and all references to the JSC
or JPT will thereafter be deemed a reference to Amgen for purposes of the
remaining provisions of this Agreement; and Micromet’s obligations under Section
4.2.3(b) will apply as if it had completed the development of all initial
manufacturing processes.
 
14.6.3    After electing to exercise its rights under Section 14.6.2, if Amgen
[***] with respect to a Product binding to a Collaboration Target (either itself
or through an Affiliate or sublicensee) during a [***] of [***], and a [***] has
[***] the [***] of such Product to [***] or [***], or [***] in [***] to [***]
(or does not [***] with respect to [***]), then, at [***] option, either (a)
Amgen will grant and (subject to the satisfaction of the terms of this Section
14.6.3) hereby grants Micromet a non-exclusive, worldwide, fully-paid,
royalty-free license (with the right to grant and authorize the further grant of
sublicenses) under any [***] Patents to [***] binding to such [***], or (b) the
[***] provisions set forth in Section [***] will be [***] as of the [***] of
such [***].
 
14.7       Rights Upon Expiration.  Upon expiration of this Agreement pursuant
to Section 13.1, the licenses granted to Amgen in Section 8.1 will become fully
paid, royalty-free and irrevocable.  Notwithstanding the foregoing, Amgen will
make any payments under any [***] and any other payments due to Third Parties
for any intellectual property rights licensed to Amgen pursuant to Section 8.3
or 8.4 of this Agreement, to the extent such financial terms have been disclosed
to Amgen pursuant to Section 8.3 or 8.4 and such payment obligations existed as
of expiration of this Agreement, for as long as such payments are due under such
agreements, and Amgen’s rights as a licensee or sublicensee under such
intellectual property rights will remain subject to Amgen’s compliance with the
payment and other terms thereof.
 
14.8       Accrued Rights.  Termination of this Agreement for any reason will be
without prejudice to any rights that will have accrued to the benefit of a Party
prior to the effective date of such termination.  Such termination will not
relieve a Party from obligations that are expressly indicated in this Article 14
to survive the termination of this Agreement.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
55

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

14.9       Survival.  Articles [***] and [***], and Sections [***] and [***],
together with any definitions used or exhibits referenced therein, will survive
any termination or expiration of this Agreement.
 
15.           Indemnification and Insurance
 
15.1       Indemnification of Micromet.  Amgen will indemnify Micromet and its
Affiliates, and their respective directors, officers, and employees (each, a
“Micromet Indemnitee”), and defend and hold each of them harmless from and
against any and all losses, damages, liabilities, costs and expenses (including
reasonable attorneys’ fees and expenses) (collectively, “Losses”) arising in
connection with any and all claims, demands, lawsuits, or investigations by a
Third Party (each a “Third Party Claim”) against a Micromet Indemnitee, to the
extent caused by or arising out of: (a) any breach by Amgen of this Agreement,
(b) the gross negligence or willful misconduct on the part of Amgen, its
Affiliates, or contractors, (c) the development, manufacture, use, handling,
storage, supply, Commercialization or other disposition of Product by Amgen, its
Affiliates or their respective sublicensees (including claims arising from or
based upon any theory of products liability), or (d) the infringement of any
Third Party Patent or misappropriation of any Third Party Know-How directed at
any [***] or [***] as a result of Micromet’s or any of its Affiliates’
performance of activities pursuant to the Development Plan or this Agreement; in
each case, excluding any Losses to the extent Micromet has an obligation to
indemnify Amgen pursuant to Section 15.2.
 
15.2       Indemnification of Amgen.  Micromet will indemnify Amgen, its
Affiliates, and their respective directors, officers, and employees (each, an
“Amgen Indemnitee”), and defend and hold each of them harmless from and against
any and all Losses arising in connection with any Third Party Claim against an
Amgen Indemnitee, to the extent caused by or arising out of: (a) any breach by
Micromet of this Agreement, (b) the gross negligence or willful misconduct on
the part of Micromet, its Affiliates, or contractors, (c) the performance of
Micromet’s development activities under the [***], (d) the manufacture, use,
handling, storage, supply, sale or other disposition of Product (including any
[***] to a [***] that [***] to be a “[***]” by reason of Section [***]) by
Micromet or its Affiliates, or contractors, (e) the breach by Micromet of the
[***] granted to Micromet under that certain [***], dated as of [***], by and
between Micromet, [***], or (f) the infringement of any Third Party Patent or
misappropriation of any Third Party Know-How directed at (i) the [***] of a
[***], the [***], the [***] the [***], or the [***] of any [***] that is a
[***], (ii) the [***] of [***], as conducted by Micromet [***] or [***] the
[***] are [***] pursuant to Section [***], or (iii) the [***] of the [***] as
incorporated into a [***], as a result of Amgen’s or any of its Affiliates’
Exploitation of the Products (but excluding any such infringement or
misappropriation claims that arise [***] on account of [***] or [***] either to
[***] or [***] the [***] of the [***] hereunder); in each case, excluding any
Losses to the extent Amgen has an obligation to indemnify Micromet and its
Affiliates pursuant to Section 15.1.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
56

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

15.3        Notice of Claim.  All indemnification claims in respect of any Amgen
Indemnitee or Micromet Indemnitee seeking indemnity under Sections 15.1 or 15.2
(collectively, the “Indemnitees” and each an “Indemnitee”) will be made solely
by the corresponding Party (the “Indemnified Party”).  The Indemnified Party
will give the other Party (the “Indemnifying Party”) prompt written notice (an
“Indemnification Claim Notice”) of any Losses or discovery of fact upon which
such Indemnified Party intends to base a request for indemnification under
Section 15.1 or Section 15.2, but in no event will the Indemnifying Party be
liable for any Losses that result from any delay in providing such notice.  Each
Indemnification Claim Notice must contain a description of the claim and the
nature and amount of such Loss (to the extent that the nature and amount of such
Loss are known at such time).  Together with the Indemnification Claim Notice,
the Indemnified Party will furnish promptly to the Indemnifying Party copies of
all notices and documents (including court papers) received by any Indemnitee in
connection with the Third Party Claim.
 
15.4       Control of Defense.  At its option, the Indemnifying Party may assume
the defense of any Third Party Claim subject to indemnification as provided for
in Sections 15.1 and 15.2 by giving written notice to the Indemnified Party
within [***] ([***])[***] after the Indemnifying Party’s receipt of an
Indemnification Claim Notice.  Upon assuming the defense of a Third Party Claim,
the Indemnifying Party may select and appoint the lead legal counsel for the
defense of the Third Party Claim.  Should the Indemnifying Party assume the
defense of a Third Party Claim, the Indemnifying Party will not be liable to the
Indemnified Party or any other Indemnitee for any legal expenses subsequently
incurred by such Indemnified Party or other Indemnitee in connection with the
analysis, defense or settlement of the Third Party Claim, except as provided in
Section 15.5.
 
15.5       Right to Participate in Defense.  Without limiting Section 15.4, any
Indemnitee will be entitled to participate in, but not control, the defense of
such Third Party Claim and to employ counsel of its choice for such purpose;
provided, that such employment will be at the Indemnitee’s own expense unless
(a) the employment thereof has been specifically authorized by the Indemnifying
Party in writing, or (b) the Indemnifying Party has failed to assume the defense
and employ counsel in accordance with Section 15.4 (in which case the
Indemnified Party will control the defense).

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
57

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

15.6       Settlement.  With respect to any Losses relating solely to the
payment of money damages in connection with a Third Party Claim and that will
not result in the Indemnitee’s becoming subject to injunctive or other
comparable relief, and as to which the Indemnifying Party has acknowledged in
writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying
Party will have the sole right to consent to the entry of any judgment, enter
into any settlement or otherwise dispose of such Loss, on such terms as the
Indemnifying Party, in its sole discretion, will deem appropriate. The
Indemnifying Party will pay all Losses on account of Third Party Claims subject
to indemnification pursuant to Section 15.1 or 15.2, as the case may be, on
behalf of the Indemnified Party at or prior to the time of the entry of
judgment.  With respect to all other Losses in connection with Third Party
Claims, where the Indemnifying Party has assumed the defense of the Third Party
Claim in accordance with Section 15.4, the Indemnifying Party will have
authority to consent to the entry of any judgment, enter into any settlement or
otherwise dispose of such Loss provided it obtains the prior written consent of
the Indemnified Party (which consent will not be unreasonably withheld or
delayed).  The Indemnifying Party that has assumed the defense of the Third
Party Claim in accordance with Section 15.4 will not be liable for any
settlement or other disposition of a Loss by an Indemnitee that is reached
without the written consent of such Indemnifying Party.  Regardless of whether
the Indemnifying Party chooses to defend any Third Party Claim, no Indemnitee
will admit any liability with respect to, or settle, compromise or discharge,
any Third Party Claim without first offering to the Indemnifying Party the
opportunity to assume the defense of the Third Party Claim in accordance with
Section 15.4.
 
15.7       Cooperation.  If the Indemnifying Party chooses to defend any Third
Party Claim, the Indemnified Party will, and will cause each other Indemnitee
to, cooperate in the defense thereof and will furnish such records, information
and testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in
connection with the defense of such Third Party Claim.  Such cooperation will
include access during normal business hours afforded to the Indemnifying Party
to, and reasonable retention by the Indemnified Party of, records and
information that are reasonably relevant to such Third Party Claim, and making
Indemnitees and other employees and agents available on a mutually convenient
basis to provide additional information and explanation of any material provided
hereunder. The Indemnifying Party will reimburse the Indemnified Party for all
its reasonable out-of-pocket expenses in connection with such cooperation.
 
15.8       Expenses.  Except as provided above, the reasonable and verifiable
costs and expenses, including fees and disbursements of counsel, incurred by the
Indemnified Party in connection with any claim will be reimbursed on a Calendar
Quarter basis by the Indemnifying Party, without prejudice to the Indemnifying
Party’s right to contest the Indemnified Party’s right to indemnification and
subject to refund in the event the Indemnifying Party is ultimately held not to
be obligated to indemnify the Indemnified Party.
 
15.9       Insurance.  During the Term [***], each Party will have and maintain
such types and amounts of liability insurance including self-insurance as is
normal and customary in the industry generally for similarly situated parties,
and will upon request provide the other Party with a certificate of insurance in
that regard, along with any amendments and revisions thereto.
 
16.           Representations and Warranties
 
16.1        Mutual Representations and Warranties.  Each Party hereby represents
and warrants to the other Party that, as of the Effective Date:

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
58

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

16.1.1    Such Party (a) has the corporate power and authority to enter into
this Agreement and perform its obligations hereunder, and (b) has taken all
necessary corporate action on its part required to authorize the execution and
delivery of this Agreement and the performance of its obligations hereunder.
 
16.1.2    This Agreement has been duly executed and delivered on behalf of such
Party and constitutes a legal, valid and binding obligation of such Party and is
enforceable against it in accordance with its terms subject to the effects of
bankruptcy, insolvency or other laws of general application affecting the
enforcement of creditor rights and judicial principles affecting the
availability of specific performance.
 
16.1.3    The execution and delivery of this Agreement and the performance of
such Party’s obligations hereunder (a) do not conflict with or violate any
requirement of any provision of the articles of incorporation, bylaws or any
similar instrument of such Party in any material way, and (b) do not conflict
with, violate, or breach or constitute a default or require any consent under,
any obligation, contractual or otherwise, or court or administrative order by
which such Party is bound.
 
16.2        Additional Representations and Warranties of Micromet.  Micromet
hereby represents and warrants to Amgen that, as of the Effective Date:
 
16.2.1    Micromet is a corporation duly organized, validly existing and in good
standing under the laws of Germany, and has full corporate power and authority
and the legal right to own and operate its property and assets and to carry on
its business as it is now being conducted and as it is contemplated to be
conducted by this Agreement.
 
16.2.2    Micromet has not received any written allegation from a Third Party
that any Patent within the [***] Technology is invalid or unenforceable and no
Patent within the [***] Technology is subject to interference, reexamination,
reissue, revocation, opposition, appeal or other administrative proceedings.
 
16.2.3    Micromet is the sole and exclusive owner of all right, title and
interest in the Licensed Technology or, as the case may be, has obtained
licenses thereto.
 
16.2.4    To the knowledge of Micromet’s officers and the head of Micromet’s
Intellectual Property department none of (i) the research and development
activities of potential Products as described in the Initial Development Plan as
of the Effective Date, (ii) the generation of BiTE Antibodies binding to the
Collaboration Target and manufacture for clinical purposes of such BiTE
Antibodies as described in the Initial Development Plan as of the Effective
Date, and (iii) the composition or use of such generated BiTE Antibodies in a
Product is claimed in any published or issued Patent of a Third Party that is
not sublicensed to Amgen under this Agreement as part of the Licensed
Technology.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
59

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

16.2.5    Micromet has not received, with respect to the Licensed Technology,
any notice of infringement or any written communication relating in any way to a
possible infringement of any Third Party patent rights by its activities prior
to the Effective Date or the activities of either Party contemplated by this
Agreement.
 
16.2.6    Micromet has the right and authority to grant the rights and licenses
granted to Amgen pursuant to the terms and conditions of this Agreement, and
Micromet has not granted any right, license, or interest in, to, or under the
Licensed Technology that is inconsistent with the rights, licenses, and
interests granted to Amgen under the terms and conditions of this Agreement.
 
16.2.7    Micromet has not placed, and to Micromet’s knowledge there does not
exist, upon the Licensed Technology any encumbrance, charge or lien (other than
licenses granted under the [***] Technology that do not violate Section 16.2.6).
 
16.2.8    The Patents listed on Exhibit C represent all Patents within
Micromet’s Control required or useful for the development, Commercialization or
Exploitation of a Product.
 
16.2.9    The Patents listed on Exhibit C have been filed and maintained in a
manner consistent with its standard practice in each applicable country in the
Territory in which such Patents have been filed and all applicable fees have
been paid on or before the due date for payment.
 
16.2.10  Other than the [***] or the agreements listed on Exhibit J, there are
no agreements in effect as of the Effective Date with a Third Party under which
rights with respect to the Licensed Technology are being licensed to
Micromet.  Neither Micromet, nor, to Micromet’s knowledge, any of the Third
Parties set forth on Exhibit D, is in breach or default under the applicable
[***].  Micromet has provided true and complete copies of the [***] to Amgen.
 
16.2.11  To Micromet’s knowledge, all inventors of inventions claimed in the
Patents listed on Exhibit C have assigned, or have a contractual obligation to
assign, their entire right, title and interest in and to such inventions to
Micromet and the inventors listed are correct and there are no claims or
assertions in writing regarding the inventorship of such Patent Rights alleging
that additional or alternative inventors ought to be listed.
 
16.2.12  None of Micromet nor any of its Affiliates, nor, to Micromet’s
knowledge, any officer, employee or agent of any of the foregoing, has been
convicted of any crime or engaged in any conduct that has resulted, or would
reasonably be expected to result, in debarment under Applicable Law, including
21 U.S.C. Section 335a or any similar state law or regulation under 42 U.S.C.
Section 1320a-7, or any similar federal, state, local or foreign regulatory
requirement, or listing in any exclusion list or program similar to the
exclusion list and program maintained by the United States Office of Inspector
General under 42 C.F.R. Part 1003.102.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
60

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

16.3       Additional Representations and Warranties of Amgen. Amgen hereby
represents and warrants to Micromet that, as of the Effective Date, Amgen is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware, and has full corporate power and authority and the
legal right to own and operate its property and assets and to carry on its
business as it is now being conducted and as it is contemplated to be conducted
by this Agreement.  Amgen further represents and warrants to Micromet that, as
of the Effective Date, to the knowledge of [***], after due inquiry based solely
on the materials Amgen has provided to Micromet prior to the Effective Date,
Amgen is [***] of any [***] of the [***] for the [***] of [***].
 
16.4       Performance by Affiliates.  Each Party (including, solely for
purposes of this Section 16.4, Micromet, Inc.), agrees to cause its Affiliates
to comply with the provisions of this Agreement as applicable to such Affiliate
and to guarantee the payment of all amounts owed by its Affiliates under this
Agreement.  Any breach by a Party’s Affiliate of any of such Party’s obligations
under this Agreement will be deemed a breach by such Party, and the other Party
may proceed directly against such Party without any obligation to first proceed
against such Party’s Affiliate.  In addition, during the Term, Micromet, Inc.
will not divest, restructure, reorganize or reclassify its Affiliates with any
intent in whole or in part to avoid, reduce or eliminate its or any of its
Affiliates’ obligations or commitments set forth in this Agreement.
 
17.           Disclaimer; Limitation of Liability
 
17.1       Disclaimer of Warranty.  EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH
IN ARTICLE 16, AMGEN AND MICROMET MAKE NO REPRESENTATIONS AND GRANT NO
WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY
STATUTE OR OTHERWISE, AND AMGEN AND MICROMET EACH SPECIFICALLY DISCLAIMS ANY
OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS,
STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR
FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF
ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD
PARTIES.
 
17.2       Limitation of Liability. EXCEPT IN THE EVENT OF A PARTY’S BREACH OF
ITS OBLIGATIONS UNDER ARTICLE 11, AND EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE
REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY
PROVIDES INDEMNIFICATION UNDER ARTICLE 15, IN NO EVENT WILL EITHER PARTY BE
LIABLE FOR LOST PROFITS, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL
OR PUNITIVE DAMAGES HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR
NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING
UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS AGREEMENT.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
61

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

18.         Miscellaneous
 
18.1       Force Majeure.  Neither Party will be held liable or responsible to
the other Party or be deemed to have defaulted under or breached this Agreement
for failure or delay in fulfilling or performing any term of this Agreement when
such failure or delay is caused by or results from events beyond the reasonable
control of the non-performing Party, including fires, floods, embargoes,
shortages, epidemics, pandemics, quarantines, war, acts of terrorism, acts of
war (whether war be declared or not), insurrections, riots, civil commotion,
strikes, lockouts or other labor disturbances, acts of God or acts, omissions or
delays in acting by any Governmental Authority.  The non-performing Party will
notify the other Party of such force majeure within [***] ([***])[***] after
such occurrence by giving written notice to the other Party stating the nature
of the event, its anticipated duration, and any action being taken to avoid or
minimize its effect.  The suspension of performance will be of no greater scope
and no longer duration than is necessary and the non-performing Party will use
commercially reasonable efforts to remedy its inability to perform.
 
18.2       Assignment.  Neither Party will assign, whether voluntarily,
involuntarily, by operation of law or otherwise, this Agreement without the
prior written consent of the other Party (which consent may be granted, withheld
or conditioned at such other Party’s sole and absolute discretion); provided,
however, that either Party may assign this Agreement whether voluntarily,
involuntarily, by operation of law or otherwise without the consent of the other
Party (a) to any Affiliate of such Party provided that such assignment will be
effective for only so long as such Affiliate remains an Affiliate, (b) to any
Third Party with which it mergers or consolidates or to which it sells,
transfers or issues a majority of the voting power of its outstanding shares, in
connection with such event (it being understood that this clause (b) shall
include any such event involving Micromet’s ultimate parent or any intervening
entity); or (c) to any Third Party to which a Party transfers all or
substantially all of its assets to which this Agreement relates.  Any such
assignment will not be effective unless and until the relevant Affiliate
assignee, Third Party assignee or surviving entity assumes in writing all of the
assigning Party’s obligations under this Agreement (it being understood that any
assignee shall assume all obligations under and assets (including intellectual
property and other proprietary rights) pertaining to this Agreement).  A copy of
such written assumption of obligations will be provided to the other Party upon
request.  Any purported assignment or transfer in violation of this section will
be void ab initio and of no force or effect.
 
18.3       Severability.  If any provision of this Agreement is held to be
illegal, invalid or unenforceable under any present or future law, and if the
rights or obligations of either Party under this Agreement will not be
materially and adversely affected thereby, (a) such provision will be fully
severable, (b) this Agreement will be construed and enforced as if such illegal,
invalid or unenforceable provision had never comprised a part of this Agreement,
(c) the remaining provisions of this Agreement will remain in full force and
effect and will not be affected by the illegal, invalid or unenforceable
provision or by its severance from this Agreement, and (d) in lieu of such
illegal, invalid or unenforceable provision, the Parties will negotiate in good
faith a legal, valid and enforceable provision that most nearly reflects the
original intent of the Parties.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
62

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

18.4       Governing Law; Dispute Resolution.
 
18.4.1      This Agreement, and any claim, dispute, or controversy of whatever
nature arising out of or relating to this Agreement will be governed by and
construed in accordance with the laws of the State of New York, without giving
effect to any principles, statutory provisions or other rules of choice of law
that would require the application of the laws of a different country.
 
18.4.2      The Parties will try to settle their differences amicably between
themselves.  If any claim, dispute, or controversy of whatever nature arising
out of or relating to this Agreement, including the performance or alleged
non-performance of a Party of its obligations under this Agreement, arises
between the Parties (each a “Dispute”), a Party will, before initiating any
proceedings pursuant to Section 18.4.3, notify the other Party in writing of
such Dispute.  If the Parties are unable to resolve the Dispute within [***]
([***])[***] of receipt of the written notice by the other Party, such dispute
will be referred to the Senior Officers of each of the Parties who will meet in
person in the U.S. or by teleconference at least once and use their good faith
efforts to resolve the Dispute within [***] ([***])[***] after such referral.
 
18.4.3      If a Dispute is not resolved as provided in the preceding Section
18.4.2, whether before or after termination of this Agreement, the Parties
hereby agree that:
 
(a)           if the Parties fail to agree on the appropriate terms of a license
to be granted under Sections [***] or [***], then the procedures set forth on
Exhibit H will apply;
 
(b)           [***] Disputes.  Disputes relating to the [***] of one or more
[***] of any [***] the [***], that, [***], would [***] the [***] of [***]
payable to Micromet under this Agreement, will be resolved by final and binding
arbitration conducted in Washington, DC, U.S.A. according to Rules of
Arbitration of the International Chamber of Commerce (“ICC”).  Amgen may
initiate such arbitration proceedings only at such time as the [***] are (or,
after the time reasonably expected for resolution of the Dispute pursuant to
this Section 18.4.3(b), would be (assuming resolution in Amgen’s favor)) the
[***] for the applicable Product in the applicable jurisdiction.  The
arbitration will be conducted by a panel of three (3) arbitrators with
significant experience regarding [***] in the [***] that is the subject of such
Dispute and regarding the pharmaceutical industry, unless otherwise agreed by
the Parties, appointed in accordance with applicable ICC rules.  The chairman of
the panel will be a U.S. national.  Any arbitration under this Section will be
conducted in the English language to the maximum extent possible.  Each Party
will have the right to take up to [***] ([***])[***] of deposition testimony,
including expert deposition testimony.  The Parties agree that the arbitrators
will set a discovery cutoff not to exceed (a) for percipient discovery, [***]
([***])[***] after the signing of the statement of the case after the
arbitrators are selected and (b) for expert discovery, [***] ([***])[***] after
the signing of such statement.  These dates may be extended by the arbitrators
for good cause shown.  The arbitrators will be instructed not to award any
punitive or special damages or other relief other than a monetary judgment for
payment of royalties due hereunder and will render a written decision no later
than [***] ([***])[***] following the signing of the statement of the case after
the arbitrators are selected, including a basis for any decision
reached.  During the pendency of such arbitration proceeding, Amgen will [***]
for the [***] of [***] the [***] of any [***] (as and when such [***] and [***]
with respect thereto (assuming such one or more [***] are [***])), with such
[***] (or [***] thereof) to be [***] upon the panel’s determination of the [***]
(based upon a finding that such [***] are [***]).  Each Party will pay its legal
fees and costs related to the arbitration (including witness and expert
fees).  Judgment on the award so rendered will be final and may be entered in
any court having jurisdiction thereof.  The existence of and materials related
to any such arbitration proceeding will be deemed Confidential Information of
the Parties hereunder; and

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
63

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

 (c)           all Disputes other than those described in Sections 18.4.3(a) and
(b) above will be resolved by the courts of competent jurisdiction located in
Washington, DC (for proceedings initiated by Amgen) or Los Angeles, CA (for
proceedings initiated by Micromet).
 
18.4.4      Nothing in this Section 18.4 will preclude either Party from seeking
equitable relief or interim or provisional relief from a court of competent
jurisdiction, including a temporary restraining order, preliminary injunction or
other interim equitable relief, concerning a dispute either prior to or during
any arbitration if necessary to protect the interests of such Party or to
preserve the status quo pending the arbitration proceeding.
 
18.5       Consequences of Change of Control.
 
18.5.1      Change of Control of Either Party.  If either Party (or any assignee
or surviving party) is involved in a Change of Control with a Third Party, the
Patents and Know-How that (i) are Controlled by such Third Party and its
Affiliates immediately prior to such Change of Control (whether such Third Party
becomes the assignee of this Agreement or if such Third Party remains an
Affiliate of such Party), or (ii) become Controlled by such Third Party
following such Change of Control (except to the extent either (A) conceived or
generated by making material use of such Party’s Patents, Know-How or
Confidential Information or (B) conceived or generated under this Agreement by a
Party or a successor entity thereto), will in each case be automatically
excluded from the definitions of [***] Technology and [***] Technology (in the
case that Micromet is involved with a Change of Control) and [***] Technology
and [***] Technology (in the case that Amgen is involved with a Change of
Control).  In the event of any Change of Control, the affected Party will
undertake reasonable safeguards to segregate such Patents and Know-How
controlled by such Third Party and its Affiliates including, by way of example,
a prohibition on non-executive [***] personnel supporting both programs, the
creation of internal procedures to limit the flow of information between project
team members, etc.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
64

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

18.5.2     Micromet Change of Control.
 
(a)           Notwithstanding anything to the contrary in this Agreement, if
Micromet undergoes a Change of Control with a Third Party that [***] (if [***])
or has [***] of [***] from [***], then in addition to the consequences set forth
in Sections 2.1.6 and 5.2, the rights granted to Micromet under Section 8.6.5
(other than with respect to any [***] Technology that constituted [***]
Technology prior to Amgen’s receipt of notice from Micromet of such Change of
Control, including any such [***] Technology then in use by Micromet) and
Section 14.1 (other than with respect to any Program Transfer that occurred
prior to Amgen’s receipt of notice from Micromet of such Change of Control) will
automatically terminate and be of no further force or effect.  Upon any
termination of this Agreement following a Change of Control as described in this
Section 18.5.2(a), Amgen will grant and (subject to the satisfaction of the
terms of this Section 18.5.2(a)) hereby grants Micromet a non-exclusive,
fully-paid, royalty-free license (with the right to grant and authorize the
further grant of sublicenses) under any [***] Patents to Exploit in the [***]
binding to any [***] with respect to which this Agreement has
terminated.  Except as expressly set forth in this Section 18.5.2(a), nothing in
this Section 18.5.2(a) will grant to Micromet any right, title or interest in
and to the [***] Patents or any other intellectual property of Amgen (either
expressly or by implication or estoppel), or any right of reference to any data
relating to any Product.
 
(b)           Notwithstanding anything to the contrary in this Agreement, if (i)
Micromet undergoes a Change of Control with a Third Party other than as
described in Section 18.5.2(a) above and (ii) Amgen has [***] relating to such
Third Party’s practices regarding the [***] or other [***], then Amgen will have
the right to [***] of any [***] or other [***] to such Third Party in connection
with any Program Transfer until such time as (in [***] and [***]) such Third
Party [***] with respect thereto.  Amgen shall provide prompt notice under this
Agreement upon any determination under this Section 18.5.2(b) as of the date any
termination notice is delivered by Amgen to Micromet but in any event prior to
the Termination Effective Date.
 
18.6       Notices.  All notices or other communications that are required or
permitted hereunder will be in writing and delivered personally, sent by
facsimile (and promptly confirmed by personal delivery or overnight courier as
provided in this Agreement), or sent by internationally-recognized overnight
courier addressed as follows:
 
If to Amgen, to:

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
U.S.A.
Attention: Corporate Secretary
Facsimile: +[***]

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
65

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

If to Micromet, to:

Micromet AG
Staffelseestr. 2
81477 Munich
Germany
Attention: Head of Business Development
Facsimile: +[***]

with a copy to:

Micromet, Inc.
9201 Corporate Boulevard, Suite 400
Rockville MD 20850
Attention: General Counsel
Facsimile: +[***]

or to such other address as the Party to whom notice is to be given may have
furnished to the other Party in writing.  Any such communication will be deemed
to have been given (i) when delivered, if personally delivered or sent by
facsimile on the same day if a Business Day and if not on the next business day
following delivery, and (ii) on the second business day after dispatch, if sent
by internationally-recognized overnight courier.  It is understood and agreed
that this Section 18.6 is not intended to govern the day-to-day business
communications necessary between the Parties in performing their obligations, in
due course, under the terms of this Agreement.
 
18.7       Entire Agreement; Modifications.  This Agreement sets forth and
constitutes the entire agreement and understanding between the Parties with
respect to the subject matter of this Agreement and all prior agreements,
understanding, promises and representations, whether written or oral, with
respect thereto are superseded by this Agreement, including the Confidential
Disclosure Agreement between the Parties dated [***].  Each Party confirms that
it is not relying on any representations or warranties of the other Party except
those that are expressly made in this Agreement.  No amendment or modification
of this Agreement will be binding upon the Parties unless made in writing and
duly executed by authorized representatives of both Parties.
 
18.8       Relationship of the Parties.  The relationship between the Parties is
and will be that of independent contractors, and does and will not constitute a
partnership, joint venture, agency or fiduciary relationship. Neither Party will
have the authority to make any statements, representations or commitments of any
kind, or to take any actions, which are binding on the other Party, except with
the prior written consent of the other Party to do so.  All persons employed by
a Party will be employees of such Party and not of the other Party and all costs
and obligations incurred by reason of any such employment will be for the
account and expense of such Party.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
66

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

18.9       Waiver.  Any term or condition of this Agreement may be waived at any
time by the Party that is entitled to the benefit of such term or condition, but
no such waiver will be effective unless set forth in a written instrument duly
executed by or on behalf of the Party waiving such term or condition.  The
waiver by either Party of any right under this Agreement or of claims based on
the failure to perform or a breach by the other Party will not be deemed a
waiver of any other right under this Agreement or of any other breach or failure
by said other Party whether of a similar nature or otherwise.
 
18.10     Counterparts.  This Agreement may be executed in two (2) or more
counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument.  This Agreement may be
executed by facsimile or electronically transmitted signatures and such
signatures will be deemed to bind each Party hereto as if they were original
signatures.
 
18.11     No Benefit to Third Parties.  The representations, warranties,
covenants and agreements set forth in this Agreement are for the sole benefit of
the Parties hereto and their successors and permitted assigns, and they will not
be construed as conferring any rights on any other parties.
 
18.12     Further Assurance.  Each Party will duly execute and deliver, or cause
to be duly executed and delivered, such further instruments and do and cause to
be done such further acts and things, including the filing of such assignments,
agreements, documents and instruments, as may be necessary or as the other Party
may reasonably request in connection with this Agreement or to carry out more
effectively the provisions and purposes, or to better assure and confirm unto
such other Party its rights and remedies under this Agreement.
 
18.13     English Language.  This Agreement has been written and executed in the
English language.  Any translation into any other language will not be an
official version hereof, and in the event of any conflict in interpretation
between the English version and such translation, the English version will
control.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
67

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

18.14     Construction.  Except where the context otherwise requires, wherever
used, the singular will include the plural, the plural the singular, the use of
any gender will be applicable to all genders, and the word “or” is used in the
inclusive sense (and/or).  Whenever this Agreement refers to a number of days,
unless otherwise specified, such number refers to calendar days.  The captions
of this Agreement are for convenience of reference only and in no way define,
describe, extend or limit the scope or intent of this Agreement or the intent of
any provision contained in this Agreement.  The term “including” as used herein
will be deemed to be followed by the phrase “without limitation” or like
expression.  The term “will” as used herein means shall.  References to “$”
herein mean United States Dollars.  When used in relation to Feasibility Targets
and Collaboration Targets, the terms “binding to”, “directed at”, “directed to”,
“targeting” and the like have equivalent meanings.  References to “Article”,
“Section” or “Exhibit” are references to the numbered sections of this Agreement
and the exhibits attached to this Agreement, unless expressly stated
otherwise.  The language of this Agreement will be deemed to be the language
mutually chosen by the Parties and no rule of strict construction will be
applied against either Party hereto.
 
[Remainder of this page is left blank intentionally]

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
68

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives as of the date first above written.

Micromet AG
 
Amgen Inc.
     
By:
/S/ JENS HENNECKE
 
By:
/S/ JONATHAN PEACOCK
Name: 
Jens Hennecke
 
Name: 
Jonathan Peacock
Title:
SVP Business Development, Vorstand
 
Title:
Executive Vice President and Chief Financial Officer
     
By:
/S/ PATRICK BAEUERLE
   
Name:
Patrick Baeuerle
   
Title:
SVP & CSO, Vorstand
         
Legal Department Review: /S/ AD
   

Micromet, Inc.*
     
By:
/S/ JENS HENNECKE
 
Name: 
Jens Hennecke
 
Title:
SVP Business Development
     
*Solely for the purpose of Section 16.4
 

[Signature Page to the Collaboration and License Agreement]
 
*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit A
 
Feasibility Targets
 
1.           [***]  (HUGO symbol = [***]; aliases = [***]; other names = [***]
identified by the UniProtKB/Swiss-Prot entry name [***] accession number [***]
with the following amino acid sequence:
 
[***]
 
2.           [***](HUGO symbol = [***]; aliases = [***]; identified by the
RefSeq-Sequenz [***] with the following amino acid sequence:
 
[***]
 
3.            [***] (HUGO symbol = [***]; aliases = [***]; identified by the
UniProtKB/Swiss-Prot entry name [***] and accession number [***] with the
following amino acid sequence:
 
[***]

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit B

Initial Development Plan
 
Amgen BiTEs Antibody - Summary of Work-Packages
 
General
 
[***]
 
Drug Discovery (Amgen & MITI)
 
Principle: [***]
 
Requirements [***]: [***]
 
Work-packages [***]: [***]
 
Deliverables [***]: [***]
 
Requirements collaboration target program: [***]
 
Work-packages collaboration target program: [***]
 
Deliverable collaboration target program: [***]
 
Process Development & Manufacturing (Amgen & MITI)
 
Principle: [***]
 
Requirements: [***]
 
Work-packages: [***]
 
Deliverables: [***]
 
Work-packages [***]: [***]
 
Deliverables: [***]
 
[***] Development: [***] (MITI)
 
Principle: [***]
 
Requirements: [***]
 
Work-packages - [***]: [***]

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Work-packages - [***]: [***]
 
Deliverables: [***]
 
[***] Development (MITI)
 
Principle: [***]
 
Requirements: [***]
 
Work-packages: [***]
 
Deliverables: [***]
 
[***] Development: [***] (MITI)
 
Principle: [***]
 
Requirements: [***]
 
Work-packages: [***]
 
Deliverables: [***]
 
[***] and [***] support
 
Requirements: [***]
 
Work-packages: [***]
 
Deliverables: [***]
 
*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit C
 

Patents within [***] Technology
 
[***]
 
Application
Number
Application
Filing Date
Country
Title of Application
Status
Patent
Number
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Application
Number
Application
Filing Date
Country
Title of Application
Status
Patent
Number
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 

 
[***]
 
Application Number
Application
Filing Date
Country
Title of Application
Status
Patent
Number
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
[***]

 
[***]

Application Number
Application
Filing Date
Country
Title of Application
Status
Patent
Number
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
[***]

 
[***]

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Application Number
Application
Filing Date
Country
Title of Application
Status
Patent
Number
[***]
[***]
[***]
[***]
[***]
[***]

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit D
 
[***]

 
[***]
[***]
[***]
[***]

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit E
 
Patent Jurisdictions

 
Patent Code
Patent Jurisdiction
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit F
 
Milestone Schedule

Milestone Event
Milestone
Payment
[***] of [***] pursuant to Section [***]
€[***]
[***] of [***] (only if applicable) pursuant to Section [***]
€[***]
[***] of [***], as described in the [***], for [***] (only if a [***] is [***])
€[***]
Earlier of (i) [***] of the [***], as described in the [***], with respect to
the [***], and (ii) [***] of [***] with respect to the [***]
€[***]
[***] for a Product
€[***]
[***] of [***] in [***] (or [***] of a [***]) of a Product
€[***]
 
The milestones below are paid by [***] and [***] (each defined below), up to
[***] per [***] (as shown on Exhibit F-2 below), and are expressed as a [***] of
the [***] shown on Exhibit F-2.
 
Regardless of the [***] of [***] or [***], the [***] of milestones payable with
respect to a [***] (including all Products [***] to the [***]) are: €[***] for
[***], €[***] for [***] and €[***] for [***].
[***] of [***] in first [***]
[***]
[***] of [***] of [***] for [***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***] for the [***] for the [***]
€[***]
[***] for the [***] for the [***]
€[***]
[***] for the [***] for the [***]
€[***]

If a milestone event described above (other than the [***] of a [***] or a [***]
relating to a [***] or [***]) is achieved that is subsequent to a preceding
milestone event with respect to which Amgen has not yet made the corresponding
milestone payment, the preceding milestone event is deemed achieved, and the
corresponding milestone payment is due and payable together with the payment of
the milestone payment for the subsequent milestone event.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

 
Exhibit F-21
 
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]

 
“[***]” means, within a [***], any [***] or [***] (or [***]) of such [***] for
which a [***], including [***] thereto.
 
 “[***]” means, with respect to a [***] for which a [***], an [***] that [***] a
[***] in the number of [***] as compared to the [***] for such [***] for which
the [***].  Each of the following would [***] a “[***]”:  (i) the [***] of a
[***] in a [***] (e.g., [***] or [***]) or [***] of [***] ([***] or [***]), or
(ii) the [***] of a [***] or [***] to a [***] that is different than the [***]
for which the [***].
 

--------------------------------------------------------------------------------

1 All amounts are expressed in Euros.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit G
 
Press Release

[logo.jpg]

Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen
-Collaboration on up to three targets and two programs
— Upfront payment of €10 million upon deal execution
-Maximum deal value of €695 million plus royalties and development cost
reimbursement

Rockville, MD, July [ ], 2011 –Micromet, Inc. (NASDAQ: MITI) announced today
that it has entered into a collaboration agreement with Amgen Inc. for the
research of BiTE antibodies against three undisclosed solid tumor targets. Amgen
will have the right to pursue development and commercialization of BiTE
antibodies against up to two of these targets, to be selected by Amgen.

“The BiTE antibody provides an innovative approach to cancer therapy,” said
Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and
Development at Amgen.  “Amgen is pleased to collaborate with the Micromet
scientific team to deploy this technology against targets for the treatment of
solid tumors.”

Under the terms of the agreement, Amgen is expected to pay €10 million upon deal
execution.  If milestones in multiple indications and tumor types are achieved,
Micromet is eligible to receive up to €342 million in clinical and commercial
milestone payments.  Micromet is also eligible to receive up to double-digit
royalties on worldwide net sales.

For the second BiTE program, Micromet is eligible to receive an additional cash
payment upon initiation of the program, milestones, royalties and development
funding comparable to the first program. The combined potential payments to
Micromet from both programs, excluding reimbursement of research and development
costs, are approximately €695 million.  The initial development plan
contemplates €25 million in R&D funding if two BiTE antibodies are advanced to
IND.  All expected costs associated with the research, development and
commercialization of the BiTE antibodies will be borne by Amgen.

Micromet will be primarily responsible for the discovery and pre-clinical
development of the BiTE antibodies. Amgen will lead the clinical development,
manufacturing, and commercialization of any products resulting from the
collaboration.

“We are very pleased to collaborate with Amgen, an industry leader with a proven
track record of success in oncology and biologics,” said Christian Itin, Ph.D.,
Micromet’s President and Chief Executive Officer. "This collaboration aligns
well with our strategy to expand development of BiTE antibodies into solid tumor
indications with support from a partner and brings important non-dilutive
capital into the company."

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

About BiTE Antibodies
BiTE® antibodies are designed to direct the body's cytotoxic, or
cell-destroying, T cells against tumor cells, and represent a new therapeutic
approach to cancer therapy. Typically, antibodies cannot engage T cells because
T cells lack the appropriate receptors for binding antibodies. BiTE antibodies
have been shown to bind T cells to tumor cells, ultimately inducing a
self-destruction process in the tumor cells referred to as apoptosis, or
programmed cell death. In the presence of BiTE antibodies, T cells have been
demonstrated to serially eliminate tumor cells, which explains the activity of
BiTE antibodies at very low concentrations. Through the killing process, T cells
start to proliferate, which leads to an increased number of T cells at the site
of attack.

About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery,
development and commercialization of innovative antibody-based therapies for the
treatment of cancer. Its product development pipeline includes novel antibodies
generated with its proprietary BiTE® technology, as well as conventional
monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103)
is currently the subject of a European pivotal trial in patients with minimal
residual disease positive acute lymphoblastic leukemia.  Micromet has
collaborations with a number of leading pharmaceutical and biotechnology
companies, including this collaboration with Amgen  and existing collaborations
with Bayer Heathcare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck
Serono, Nycomed and Sanofi.  Additional information can be found at
www.micromet.com.

Safe Harbor Statement
This release contains certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially different from
historical results or from any future results expressed or implied by such
forward-looking statements. These forward-looking statements include statements
regarding the operation of the collaboration with Amgen, the efficacy, safety
and intended utilization of our product candidates, including the BiTE
antibodies that are the subject of the agreement with Amgen, the mode of action
of BiTE antibodies, the conduct, timing and results of future clinical trials,
expectations of the future expansion of our product pipeline and collaborations,
the initiation of a second BiTE program under the collaboration with Amgen and
the future payment of upfront, milestone and royalty payments by Amgen. You are
urged to consider statements that include the words "ongoing," "may,"
“eligible,” "will," "believes," "potential," "expects," "plans," "anticipates,"
"intends," or the negative of those words or other similar words to be uncertain
and forward-looking. Factors that may cause actual results to differ materially
from any future results expressed or implied by any forward-looking statements
include the risk that our product candidates do not demonstrate safety and/or
efficacy in pre-clinical studies or clinical trials, delays in development and
testing, including the risk that Amgen will not obtain approval to market our
product candidates and the risks associated with reliance on collaboration
partners such as Amgen and outside financing to meet capital requirements. These
factors and others are more fully discussed in Micromet's Annual Report on Form
10-K, as amended, for the fiscal year ended December 31, 2010, and Micromet’s
Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011, filed
with the SEC on May 10, 2011 as well as other filings by the Company with the
SEC.

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Contact:
Jennifer Neiman
Director, Corporate Communications
Micromet, Inc.
240-235-0246
jennifer.neiman@micromet.com

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit H
 
Dispute Resolution Procedures for Certain Matters
 
1.
The Parties will resolve disputes stipulated in Sections [***] and [***] by
final and binding expertise proceedings in accordance with this Exhibit H.  The
Parties will select a mutually agreeable expert who has significant relevant
experience in the subject matter of the disputed issue and no affiliation or
pre-existing relationship with either Party.  If the Parties cannot agree on an
expert within [***] ([***])[***] after the referral of the matter to be resolved
pursuant to this Exhibit H, either Party may request the appointment of the
expert in accordance with the provisions for the appointment of experts under
the Rules for Expertise of the International Chamber of Commerce.  The date on
which such expert is selected will be the “Expertise Proceedings Commencement
Date.”

 
2.
Each Party will prepare and, within [***] ([***])[***] after the Expertise
Proceedings Commencement Date, deliver to both the expert and the other Party a
written memorandum setting forth (i) the Party’s last draft of such license
agreement provided to the other Party without any alteration, (ii) a detailed
list of open issues in such license agreement, and (iii) its position and
proposed resolution with respect to each open issue in the detailed list (the
“Support Memorandum”).  The expert will also be provided with a copy of this
Agreement.

 
3.
Within [***] ([***])[***] after the receipt of both Support Memoranda, the
expert will select from the two proposals provided by the Parties the proposal
that the expert believes [***] the [***] of the Parties to this Agreement and
the [***] the [***] and [***] of [***].  The expert’s decision will be provided
in writing.

 
4.
The expert will have reasonable discretion to request additional information,
hold a hearing, and extend the time frame for reaching his or her decision
regarding the dispute at issue; provided, that each Party will have the right to
receive a copy of any additional information or be present during any oral
submissions provided by the other Party to the expert.  For clarity, it is
understood that the Parties intend the proceedings under this Exhibit H to be a
“baseball arbitration” type proceeding.

 
5.
The expertise proceedings set forth in this Exhibit H will be conducted in the
United States.  The expert’s fees and expenses will be shared equally by the
Parties.  Each Party will bear and pay its own expenses incurred in connection
with the expertise proceedings set forth under this Exhibit H.

 
*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

6.
The Parties agree that the decision rendered by the expert will be the sole,
exclusive and binding remedy between them regarding such Dispute and the terms
and conditions in the license agreement selected by the expert will be legally
binding and enforceable between the Parties.  The expertise proceedings and the
decision of the expert will not be made public without the joint consent of the
Parties, and each Party will maintain the confidentiality of such proceedings
and decision unless each Party otherwise agrees in writing; provided, that
either Party may make such disclosures as are permitted for Confidential
Information of the other Party under Article 11 above.

 
*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit I

[***]
 
If Amgen [***] a Product for the [***] of [***] (the “[***]”), then Micromet
will have a [***] to [***] in the [***] for such Product within the [***] in the
[***] (the “[***]”), as set forth in this Exhibit I.   Micromet’s [***] in such
[***] under the [***] will be conducted pursuant to a [***] for Products that
are [***] in the [***] for the treatment of [***] (“[***]”).
 
1.1     Exercise.  Amgen will notify Micromet in writing promptly following
Amgen’s initiation of the [***] under this Agreement for an [***] within the
[***] (“[***]”).  To [***] the [***], Micromet will notify Amgen, in writing, no
later than [***] ([***])[***] after receiving such [***] (“[***]”).  The [***]
will specify the [***] of [***] (up to [***]) that Micromet desires to [***] for
the [***] in the [***].
 
1.2     Key [***] Terms.  The [***] will be [***], but will contain and be
consistent with the following terms and conditions:
 
1.2.1             The Parties will [***] to [***] on an [***] in [***], taking
into account [***] and [***], as well as [***] and [***] so as not to [***]
hinder the [***] of the [***].
 
1.2.2             [***] will [***] an [***] intended to approximate the [***]
that [***] by a [***] for [***].
 
1.2.3             Micromet will have the right to [***] its [***] by [***]
([***])[***] written notice to Amgen, and the Parties will cooperate to [***]
such [***] to Amgen with a [***] of [***].
 
1.2.4             Amgen will have the [***] to [***] of the [***].
 
1.2.5             Amgen will [***] all [***] of the [***].
 
1.2.6             Amgen will [***] all [***] and [***] for the [***].

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------

 

***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4), and 240.24b-2

Exhibit J

Certain [***]
 
[***]
 
[***]
 
[***]

*** Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 
 

--------------------------------------------------------------------------------